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1.  Short Summary 
Bio-nano interactions can be considered as the sum of complex processes and 
reactions occurring when nanoparticles (NP) get in contact with living systems. 
Regarding deposition of NPs in the lungs, interactions with the here primarily 
encountered biological matter, i.e. pulmonary surfactant (PS) are of particular interest, 
as they might play a significant role the further biological fate of such systems. 
Therefore, the central topic of this work was to investigate the binding of relevant 
components from PS to model NPs with chemically differing surface modifications. 
Moreover, effects of PS biomolecules on NP uptake by alveolar macrophages (AM) as 
the main clearance pathway for particulate matter from the peripheral lungs were 
studied. It could be demonstrated that adsorption of surfactant proteins A (SP-A) and 
D (SP-D) to NPs occurs in a manner primarily dependent on particle material 
properties. In addition, the further interaction of such protein-particles complexes 
with AMs is greatly influenced by these proteins. Furthermore, it could be shown that 
surfactant lipids can modulate such protein-mediated effects, leading to the overall 
conclusion that the complex interplay of PS components potentially assimilates the 
AM clearance of NPs, regardless of their surface properties. In summary, these findings 
contribute to a better understanding of how NP-based systems interact at the air-
blood-barrier. 
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2.  Kurzzusammenfassung 
Wenn Nanopartikel (NP) mit lebenden Systemen in Kontakt kommen, laufen 
komplexe Prozesse und Reaktionen ab, die in ihrer Gesamtheit als Bio-Nano-
Wechselwirkungen (Ww) beschrieben werden. Hinsichtlich der Abscheidung von NP 
in der Lunge sind die Ww mit den dort vorzufindenden Strukturen von besonderem 
Interesse. Gerade die Bestandteile des pulmonalen Surfactants (PS) können hier eine 
Schlüsselrolle einnehmen und biologische Reaktionen in Folge ihrer Ww mit NP 
maßgeblich beeinflussen. Im Rahmen dieser Arbeit wurde daher das 
Bindungsverhalten von Bestandteilen des PS an Modell-NP in Abhängigkeit ihrer 
Oberflächeneigenschaften getestet. Zudem wurde der Einfluss von PS–Bestandteilen 
auf die zelluläre Aufnahme durch Alveolarmakrophagen (AM) untersucht, welche 
essentiell zur Elimination von Partikeln aus der Lunge beitragen. Es konnte 
nachgewiesen werden, dass die Adsorption von Surfactant Protein A (SP-A) und D (SP-
D) vor allem von NP-Materialeigenschaften abhängig ist, und dass die adsorbierten 
Proteine die AM-Aufnahme von NP erhöhen. Es wurde zudem gezeigt, dass Surfactant 
Lipide in der Lage sind, proteinvermittelte Effekte zu modulieren. Insbesondere konnte 
eine Angleichung der Aufnahmerate von unterschiedlichen NP durch AM beobachtet 
werden, welche dem komplexen Zusammenspiel der verschiedenen PS-Bestandteile 
zuzuschreiben ist. Insgesamt tragen die hier vorgestellten Ergebnisse zu einem 
besseren Verständnis des Verhaltens von NP an der Blut-Luft-Schranke bei. 
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3.  General Introduction 
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3.1.  Lung Morphology and Particle Inhalation 
The human lungs have a total surface area of between 70 and 140 m2, and are thus the 
largest epithelium of the human body that is in direct contact with the surrounding 
environment [1, 2]. Consequently, the lungs represent the main entrance portal for 
particles into the body. Particle inhalation and subsequent interactions with the 
pulmonary structures have been and still are of tremendous interest for diverse 
scientific disciplines. The extent to which particle inhalation and deposition occurs is 
affected by (i) the lung anatomy as well as the (ii) the breathing pattern of the 
individual, and by (iii) the aerodynamic properties of the particles [3]. 
To comprehend the overall structure of the lungs, it is useful to imagine an inverted 
tree: the trunk and the branches represent the conducting airways, whereas the leaves 
can be considered as the gas-exchanging alveoli [4]. Hence, regarding their 
functionality, the lungs can be divided into a conducting zone, enabling rapid and 
effective transport of inspired air from the proximal to the distal lungs, and a 
respiratory zone that allows sufficient exchange of oxygen and carbon dioxide with 
the blood. According to its functions, the epithelium in the conducting airways differs 
substantially from that found in the peripheral lungs (Figure 3.1). 
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Figure 3.1. Cellular and Non-Cellular Elements of the Pulmonary Air-Blood-Barrier.  
Trachea and bronchi (A) are lined with a thick fluid layer, composed of the Luminal Mucus Layer (LML) 
and Periciliary Layer (PCL). The basal connective tissue is interfused with capillaries (1) and muscle fibers 
(2). Mucus is produced by goblet cells (3) and submucosal glands, and propelled by ciliated cells (4). This 
fluid layer decreases in thickness starting from the bronchioles (B), to a final value of 0.09-0.89 µm [5] in 
the alveolar region, where pulmonary surfactant (PS) mainly covers the epithelium (C). Here, alveolar 
type I cells (5) cover the main part of the surface. Type II cells (6) secrete PS and may be progenitive to 
type I cells. Airway macrophages patrol all pulmonary surfaces (7) and may cross the non-cellular 
barriers. Alveolar macrophages (8) can be characterized by close proximity to the air-liquidinterface and 
form the first line of defense in the peripheral lungs (modified after Sturm et al. [6] with permission from 
Elsevier). 
 
In the peripheral lungs, the main function of the epithelium is to provide a large and 
thin surface to facilitate gas exchange. Therefore, the squamous epithelium in this 
region is comprised of an extremely thin cell monolayer consisting of two major cell 
types: alveolar type I (AT1) and alveolar type II (AT2) cells [4]. AT1 cells only account 
for 10% of the alveolar cell number, whereas they cover more than 90% of the surface 
area in the peripheral lungs due to their extremely outstretched morphology [7, 8]. 
AT2 cells are more cuboidal in shape and mainly serve as secretory cells for pulmonary 
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surfactant (PS). It is believed that AT2 cells also act as progenitors to AT1 cells, 
although there is evidence that other cells can also proliferate into AT1 cells [8]. 
Towards the proximal end of the respiratory tract, the thickness of the epithelium 
progressively increases to a distinct cellular barrier in the bronchi and the trachea. The 
dominating cell types forming the pseudostratified epithelium in this part of the lungs 
are secretory (mucus, goblet, serous or Clara), basal and ciliated cells, whereas the 
latter account for 50% of the total cell population [8]. 
The functional sectioning of the lungs into a conducting and a gas-exchanging part is 
not only reflected by the varying cell types in the epithelium, but also by changes in 
the non-cellular elements of the lung surface lining. In the conducting airways, the 
lung surface lining mainly consists of mucus, whereas in the deep lungs, PS is most 
prevalent (compare Figure 3.1). These non-cellular structures are the first biological 
matter lung deposited particles get in contact with. 
Deposition (i.e. when inhaled particles collide with the lung surface lining) depends on 
aerodynamical properties of the particle, whereas three main deposition mechanisms 
are known: (i) impaction, (ii) sedimentation and (iii) diffusion [9]. All three 
mechanisms depend on the aerodynamic diameter (dae) of the particle, which is 
defined as the diameter of a sphere with a unit density of 1 g/cm3 having the same 
gravitational settling velocity as the considered particle [9]. Whereas impaction occurs 
in the large upper airways and is relevant for particles with dae above 5 µm, particles 
with dae between 1-5 µm deposit efficiently via sedimentation in the terminal bronchi 
and alveolar region (Figure 3.2). Particles with dae smaller 0.5 µm (e.g. nanoparticles) 
deposit by diffusion, and can also reach the deep lungs, but are easily exhaled again [9, 
10]. 
 
Chapter 3: General Introduction 
 7 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Particle Deposition as a Function of Aerodynamic Diameter. 
Particles larger than 5 µm impact in the mouth and throat, whereas particles between 1-10 µm deposit in 
the airways, mostly by sedimentation. Maximal alveolar deposition occurs with particles between 1 to 5 
µm (deposition maximum around 2 µm). Particles smaller than 100 nm are also efficiently deposited in 
the deep lungs, mainly driven by diffusion (adopted from [4] with permission from Nature Publishing 
Group). 
 
The emergence of nanotechnology and the herewith-related controversy on the 
technical but also medicinal exploitation using nanoparticles has attracted even more 
attention to inhalation of nanoparticles [11, 12]. Interestingly, across the literature in 
the field, one can find varying definitions of the term nanoparticle, actually depending 
on the context and respective scientific community. For instance, according to 
Oberdörster, one of the pioneers in the relatively new discipline of Nanotoxicology, 
only particles smaller than 100 nm in diameter are actually considered as 
nanoparticles [13]. However, in the pharmaceutical context, nanoparticles can be 
generally defined as solid colloidal particles with a diameter between 1 and 1000 nm 
[14]. 
The use of these materials raises safety concerns regarding work place exposition and 
concentrations when handling or processing nanoparticle-containing materials on the 
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one hand. Depending on the ambience an individual is located in, a large number of 
airborne particles can be inhaled with each single breath, and long-term risks from 
lung retention of nanoparticles need to be evaluated [12, 15]. However, medicinal use 
of nanoparticles as drug delivery systems or contrast agents holds promising 
opportunities, opening the field for Nanomedicine to improve pharmaceutical 
products or diagnostics on the other hand [16]. In this respect, the pulmonary route is 
an attractive site for the intended administration of nanoparticle-containing 
formulations to either locally or systematically deliver drugs to the body. 
 
Nevertheless, regardless whether a “nanomedicinal” or a “nanotoxicological” research 
question is asked, there is one intersection that applies to both disciplines: the fact 
that there is only little known on the subsequent processes following inhalation and 
deposition of nanoparticles, frequently raising the question “what happens after 
landing?” [17, 18]. 
 
The main important aspects for the fate of the particle after deposition are dissolution, 
disintegration, surface modifications due to binding of biomolecules and clearance. 
After initial contact with most outer non-cellular pulmonary structures, i.e. mucus or 
PS, an inhaled nanoparticle is likely to be altered by its surrounding environment. On 
the particle side, the binding is most likely influenced by general particle 
characteristics, such as size, shape or curvature, and surface properties, i.e. charge, 
roughness, and hydrophobicity [19]. 
Regardless of whether the conducting airways or the alveolar epithelium is the site of 
deposition, soluble compounds (i.e. proteins, glycoproteins, lipids) are secreted by 
respective cells in both compartments of the lung (e.g. goblet cells in the airways, or 
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AT2 cells in the alveoli) and can bind to particles once they have landed. Among these 
biomolecules, proteins are probably the dominant components, whereas lipids or salts 
may play a mediating role in such particle-protein interactions. In principle, the 
phenomenon of protein adsorption to foreign materials in the body is actually an issue 
that has already been investigated for more than 30 years when protein adsorption to 
surfaces in e.g. biocompatibility studies of implants was investigated [20-22]. 
Furthermore, particulate matter in the nano-scale range has been evaluated with 
respect to plasma protein adsorption actually already end of 1990s [23-25]. However, 
the topic of proteins adsorption to nanoparticles and its relevance for further 
biological effects has been recently reloaded with respect to the ongoing discussions 
on Nanosafety, and is nowadays described in the so-called protein corona theory [26, 
27]. The corona theory is an illustrative concept to describe the complex processes and 
reactions occurring when nanoparticles get in contact with living systems, also 
referred to as bio-nano interactions [27]. So far, this theory has been restricted to 
systems that are applied intravenously. Within the lungs, however, relatively little is 
known about how such biomolecules influence clearance and translocation of inhaled 
particles. In this contest, especially the role of PS regarding the clearance of 
nanoparticles by alveolar macrophages (AM) has been addressed only marginally in 
the past. 
Therefore, both the basics of the PS system as well as of AMs will be discussed in the 
following sections. 
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3.2.  Basics of Pulmonary Surfactant 
3.2.1. Molecular Composition and Functions 
The first biological, essentially non-cellular barrier an inhaled nanoparticle or 
nanoparticle-containing formulation will encounter in the peripheral lungs is the 
alveolar lining fluid (ALF) [28], sometimes also referred to as alveolar lining layer [29]. 
In contrast to the lining layer in the conducting airways, i.e. mucus, which is a rather 
thick layer, the ALF is an ultra-thin liquid layer (thickness between 90 - 890 nm; area-
weighted average about 200 nm [5]) covering the epithelial tissue in the alveolar 
region of the lungs (Figure 3.3). 
 
 
Figure 3.3. Nomenclature and Dimensions of the Pulmonary Non-Cellular Barriers.  
aAccording to Sims et al. [30]; bAssuming an airway surface area of 2 m2 and an average thickness of 5-8 
µm [30, 31]; cAccording to Bastacky et al. [5]; dAssuming an alveolar surface are of 70-140 m2 and an 
average thickness of 0.2 µm [32] [1, 5]. The term subphase is also referred to as hypophase. 
 
An integral part of the ALF is pulmonary surfactant (PS), a lipoprotein complex 
organized in large extracellular membranes, which are located at the air-liquid 
interface of the lungs. This layer is described to be continuous from the alveolar to the 
conducting airways [5, 33]. Analysis of bronchoalveolar lavage (BAL) revealed PS as a 
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mixture composed of about 90% lipids and 10% proteins by weight, whereas about 6-
8% account for the specific surfactant-associated proteins [34, 35]. 
Within the lipid fraction, about 80-85% by weight are phospholipids and 5-10% is 
cholesterol as major neutral lipid [35]. Among phospholipids, approximately 75% are 
phosphatidylcholine species, whereas the largest part comprises 
dipalmitoylphosphatidylcholine (DPPC) with about 50% by weight. Besides 
phosphatidylcholine, about 10-15% are phosphatidylglycerol and phosphatidylinositol, 
and around 5% by mass are phosphatidylserine and sphingomyelin [34, 35]. Regarding 
surfactant-associated proteins, four surfactant proteins (SP) are known to date: SP-A, -
B, -C and SP-D. The small SP-B and SP-C (17.4 kD and 4.2 kD, respectively) are 
extremely hydrophobic proteins and highly associated with lipids [36]. Together with 
the lipid fraction of PS, they form an entity with biophysical functions of outmost 
importance as they enable lipids secreted by AT2 cells to be promoted to the air-liquid 
interface of the alveolus. Here, they can spread to form a monolayer with their 
hydrophobic tail towards the air-phase. By doing so, the surface tension in the lungs is 
reduced and alveoli are thereby prevented from collapsing [34]. Overall, the formation 
of highly complex lipid membranes from which lipids are exchanged, and spread to 
the air-interface to allow normal breathing is crucially dependent on SP-B and SP-C 
[37]. 
 
In contrast, SP-A and SP-D are large proteins of a rather hydrophilic nature. They 
belong to the family of the so-called collectins [38], and show large structural 
similarities (Figure 3.4). 
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Figure 3.4. Overall Structure of Surfactant Protein A and D. 
SP-A (in blue) has a bouquet like structure. SP-D (in red) has a cruciform shaped structure. Regions in the 
primary structures found with SP-A and SP-D are shown in the box on the left. CRD stands for 
carbohydrate recognition domain [38]. 
 
With respect to their primary structure, the two proteins feature 4 similar regions: (i) 
a N-terminus that contains cystein residues; (ii) a collagen-like domain; (iii) an α-
helical rich neck region; and (iv) a C-terminal carbohydrate recognition domain (CRD) 
[38, 39]. Both proteins undergo posttranslational modifications and are assembled into 
large oligomeric structures. SP-A has an overall structure that often is described as a 
tulip bouquet, consisting of six subunits of each about 105 kD and a total molecular 
weight of about 630 kD [38]. One subunit is composed of 3 polypeptide chains, 
whereas the molecular weight of these SP-A monomers can vary between 26-38 kD, 
depending on posttranslational glycosylation [36, 40]. The primary structure of SP-D 
principally features the same regions as SP-A, but the overall structural organization is 
different. SP-D has a molecular weight of about 520 kD and consists of four oligomeric 
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subunits of 130 kD, being assembled together into a cruciform shaped structure 
(compare Figure 3.4). Each subunit here is composed of three monomeric units of each 
43 kD [38]. Apart from its cruciform shape, SP-D can also exist in multimeric 
macromolecular compositions of up to eight SP-D molecules [38]. 
Both SP-A and SP-D can be considered as multifunctional proteins. The major role of 
SP-A and SP-D assigns them to the host immune defense system. However, SP-A also 
plays an important role in lipid organization and formation of tubular myelin, and 
hereby contributes to a proper biophysical functionality of PS [41]. Their interactions 
with pathogens such as bacteria or viruses, and essentially also non-living particles 
that reach the deep lungs is of outmost importance to maintain sterility of the 
alveolus, and are therefore discussed in the following section. 
3.2.2. Functions of SP-A and SP-D 
Their association with surfactant lipids locates SP-A and SP-D directly at the air-liquid 
interface of the air-blood barrier, which enables them to efficiently interact with any 
kind of airborne materials deposited in the deep lungs. Generally, the pulmonary 
collectins act by three mechanisms: (i) opsonization of inhaled pathogens or particles; 
(ii) activation of immuno-competent cells such as AMs, neutrophils or dendritic cells 
(DC); and (iii) regulation of cellular responses, such as release of cytokines or 
expression of surface receptors. Taken together, these mechanisms result in control of 
infections, lung allergies as well as inflammatory processes [38, 42]. Due to their large 
oligomeric structures, SP-A and SP-D can be considered as broadly selective opsonins 
with high avidity, allowing them to tightly bind biological structures and patterns 
present on bacteria, viruses, fungi or yeast [38, 43, 44]. Especially the broad variety of 
structures bound by SP-A is remarkable, for which reason this protein is sometimes 
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referred to as a Swiss knife protein within the surfactant community. Among the 
chemical motifs bound by SP-A and SP-D are mainly carbohydrates such as mannose, 
glucose or fucose, but also lipid structures such as DPPC, phosphatidylinositol, but also 
lipopolysaccharide [38, 44]. By binding to patterns on the pathogen surfaces, SP-A and 
SP-D enhance phagocytosis by e.g. AMs, and therefore clearance of pathogens. This can 
occur via a direct interaction, i.e. that the surfactant protein binds to the pathogen 
surface and promotes its cellular uptake due to receptor interaction [43]. However, it 
is also possible that aggregation of pathogen structures occurs, leading to increased 
uptake without a direct interaction between the surfactant protein and the phagocyte 
[43]. Besides opsonization, SP-A and SP-D are capable to directly activate immune 
cells, which can lead to induction of chemotaxis, production of reactive oxygen species 
to efficiently coordinate and trigger the combat of infections [38, 45]. Furthermore, 
these two proteins are also able to regulate the activity of immune cells in 
inflammatory processes and contribute hereby to the homeostasis of pulmonary 
defense system [43]. 
 
Regarding interactions with solid particles such as nanoparticles, which generally will 
be recognized as foreign materials, similar mechanisms are likely to occur as known 
for biological invaders. Interaction of nanoparticles with PS components might have an 
tremendous impact on their biological further fate. However, this topic has been 
addressed only marginally in the past. State of the art of bio- nano interactions in PS is 
briefly reviewed in section 3.3. 
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3.3.  Bio-Nano Interactions in Pulmonary Surfactant 
Schürch et al. showed that upon the first contact with PS, an inhaled particle is 
immediately displaced into the ALF, due to wetting with phospholipids and resulting 
high surface pressure [46]. Furthermore, particle displacement into the ALF was 
shown to be independent of the particle surface roughness and also the anatomical 
site of the lungs deposition in hamster lungs [29]. The effect of particle size on particle 
displacement is not well known, but it is likely not a major factor in this phenomena. 
Concerning the interaction of inhaled particles – and especially nanoparticles – with 
PS, there are two compelling points of view. On the one hand, nanoparticles can have 
implications on the biophysical functionality of PS, which has been the subject of 
numerous studies in the recent past [47-50]. Overall, these studies showed that 
nanoparticulate matter potentially interferes with the PS function. Impediment of the 
surface tension reducing functions or even disruption of the PS film are a potential risk 
with respect to Nanosafety aspects, making it a crucial parameter to be elucidated for 
inhalable particles in the nanometer range. On the other hand, components of PS –  
surfactant proteins and lipids – can adsorb to nanoparticles once submerged in the so-
called aqueous subphase of PS. Adsorption of PS components to nanoparticles as a 
consequence of particle displacement into the surfactant layer might then lead to a 
pulmonary surfactant corona, possibly influencing the further biological fate of 
nanoparticles (Figure 3.5). 
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Figure 3.5. Bio-Nano Interactions at the Air-Blood-Barrier.  
After nanoparticle (NP) deposition, surfactant proteins and lipids are likely to adsorb to the NPs, leading to 
a pulmonary protein corona that may influence the further biological response such as AM clearance or 
translocation across the epithelium. 
 
Gasser et al. demonstrated that binding of phospholipids to carbon nanotubes occurs, 
and that such a phospholipid coating also influences the binding pattern of plasma 
proteins, when subsequently incubated in blood plasma [51]. These findings indicate 
that nanomaterials, which enter the body via the pulmonary route, may be altered in a 
way that “secondary protein adsorption” and thereby cellular effects or biodistribution 
via the blood stream may be varied through such a pulmonary pre-coating. 
Furthermore, concerning cellular interactions with AMs, phospholipids have been 
shown to reduce the phagocytosis of microparticles by AMs, when adsorbed to the 
particle surface [52, 53]. 
Of great interest, however, are the interactions of nanostructures with the pulmonary 
collectins SP-A and SP-D. As these two proteins are involved in macrophage-mediated 
removal of foreign material, they might play a key role also in clearance of 
nanoparticles. Due to their immense surface area, nanoparticles show the tendency to 
bind molecules from the surrounding environment to reduce their high surface energy 
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[54]. Astonishingly, there is only sporadic information available with respect to 
inhaled nanoparticles, and investigation of adsorption of surfactant proteins and lipids 
to such systems as well as consequences of such bio-nano interactions in the 
peripheral lungs are a topic which is still in its infancy [11]. So far, material dependent 
binding of SP-A and SP-D to nano-structured systems such as Carbon nanotubes, gold 
or metal oxide nanoparticles could be demonstrated [55-57]. Furthermore, there were 
few studies in the past addressing effects of PS components on AM–uptake of particles 
in the micrometer range, in which these particles were used rather as a model to test 
phagocytotic activity and to elucidate other cellular effects [58, 59]. 
However, there was no comprehensive approach so far in which both the binding of 
surfactant proteins and lipids to nanoparticles, as well as cellular responses were 
studied. Generally, besides translocation across the alveolar epithelium, another such 
possible cellular response likely to occur is the interaction with AMs, professional 
phagocytes which patrol the alveolar space in order to detect and remove foreign 
materials from the peripheral lungs. The role of AMs regarding clearance of (nano-) 
particles is therefore highlighted in the next section.  
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3.4.  Clearance of Nanoparticles from the Peripheral Lungs 
Inhalable particles, for instance originating from volcano emissions, have been 
constantly a factor influencing the evolution of the human lungs, eventually resulting 
in efficient defense mechanisms against such foreign material. In the conducting 
airways, mucus, a complex layer mainly composed of glyco-proteins and water with 
about 1-10 µm in thickness, forms a highly protective barrier towards the luminal side 
of the airways [60]. Due to the fact that the mucus blanket is propelled by ciliated 
epithelial cells, deposited material such as bacteria or even viruses, but also micro- 
and nanoparticles is efficiently transported to the proximal end of the airways; a 
process generally described a mucociliary clearance [61, 62]. 
Besides mucociliary clearance, removal of particulate matter from the lungs is mainly 
mediated by surface macrophages. In the conducting zone of the lungs, airway 
macrophages cooperate with mucociliary clearance in terms of particle clearance. In 
the peripheral lungs, however, it is the AM that is discussed to be the most important 
phagocyte in terms of particle uptake and clearance [63]. 
AMs are resident mononuclear phagocytes that derive from hematopoietic stem cells 
in the bone narrow, and reach the alveolar tissue as monocytes via the blood where 
they move to the luminal side of the lungs to become AMs [63]. AMs are the only 
macrophages in the body that are in close proximity to an air-interface and exposed to 
air. They are a major cellular component in the ALF - about 80% of cells recovered from 
a human BAL are AMs - and therefore, present in high numbers: about 5,990 x 106 AMs 
in a human lung [7, 64], which is about 12.4 AMs per alveolus [63]. 
With the lungs being the largest epithelial tissue exposed to the surrounding 
environment, AMs fulfill a crucial function in pulmonary immune reactions and the 
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host defense system, and can be considered as the first line of defense against foreign 
material reaching the alveolar environment [65, 66]. Using their actin skeleton to 
spread out tiny filaments (pseudopodia), AMs are highly mobile cells with an area of 
movement of about 18.8 µm2 per cell [63]. This allows AMs to patrol the alveolar space 
and quickly arrive on site in response to stimuli. Once they have reached the site of 
action, they can secrete a wide variety of mediators such as reactive oxygen species, 
TNF-α, chemokines and complement components. Overall, AMs are crucially involved 
in recovering the alveolar architecture and maintaining sterility in the peripheral 
lungs [65]. 
Once a particle is deposited in to the peripheral lung it will be displaced into the 
subphase where interaction with AMs is most likely [46, 67]. The main process of 
particle uptake by AMs is phagocytosis. However, before this process occurs, it is very 
likely that deposited particles are opsonized with soluble components of the ALF 
(compare section 3.2). Confrontation with AMs depends on the contingency of their 
presence at the site of deposition, but it is also possible that further AMs are directed 
towards the particulate matter via chemotaxis, until close proximity to the foreign 
material is reached [66]. 
Phagocytosis in general can be defined as an actin – dependent uptake of particles 
larger than 500 nm by immune cells [68]. This energy – dependent process takes place 
upon polymerization of actin into organized structures, leading to membrane 
extensions that can engulf the particle [63]. Other cells with phagocytic activity 
besides macrophages are neutrophils and DC, where the latter show a lower activity 
for uptake of particles [63, 69]. 
On the other hand, there are several particle parameters that can influence the uptake 
by AMs. For instance, in terms of particle size it has been shown that active particle 
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uptake via phagocytosis occurs primarily in range between 1-5 µm (geometric 
diameter) [70, 71], whereas particles less than 500 nm are taken up sporadically and 
by non-specific mechanisms [72, 73]. As outlined before, particles in the micrometer 
range are likely to be taken up mainly via active phagocytosis. However, this is 
unlikely for nanoparticles. The uptake here is probably also size dependent, using 
other pathways than phagocytosis: whereas nanoparticles bigger than 0.2 µm are 
probably taken up via pinocytosis, smaller particles (less than 150 nm) can be 
internalized via calveolae (50-100 nm) or clathrin-mediated (100-120 nm) uptake 
[63]. 
Furthermore, particle shape can determine whether a particle is internalized or not.  
Champion et al. showed that the overall shape is not the primary factor influencing 
this effect, but the local shape, i.e. the shape of the particle at the position where initial 
cell contact is made [74]. Here, they successfully showed that aspherical particles with 
high aspect ratios were internalized to an increased degree when the macrophage 
approached the particle at points with high curvature, whereas spherical particles 
were shown to be internalized from each side equally. Besides the particle shape, the 
material itself affects particle uptake by AMs. For example, increased mechanical 
robustness and overall stiffness of particles leads to increased phagocytosis [63]. More 
importantly, the material composition of a particle can affect the adsorption of 
biomolecules with opsonin function, which is likely to influence the uptake by AMs 
significantly [53, 59]. 
Upon the interaction with (nano-) particles, AMs can induce and trigger inflammatory 
reactions. Release of TNF-α, IL-1α, and IL-1β can occur, leading to expression of 
adhesion molecules and release of other chemokines and growth factors [66]. Pozzi et 
al. showed that exposure of macrophages to fine particulate matter (~ 40 nm in 
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geometric diameter) lead to increased levels of TNF-α [75]. Particles with a dae below 
100 nm can induce generation of reactive oxygen species, causing oxidative stress in 
AMs [76]. 
In contrast, AMs also control inflammation by release of chemokine inhibitors or  
TNF-α soluble receptors [77], or can self-regulate inflammatory processes via 
production of IL-10, which can then reduce release of IL-1 or TNF-α [78]. 
Furthermore, AMs can also interact with other immune cells during inflammatory 
situations induced by particulate matter. For instance, DCs are situated above and 
underneath the airway epithelium. They can extend their dendrites between epithelial 
cells to sample the luminal space for antigens and are able to report antigenic 
information to the pulmonary lymph nodes [66]. Thereby, they are able to interact 
with particle carrying AMs and can even receive particles from these cells. Blank et al. 
demonstrated that upon such a cell-cell interaction, particles even can be transferred 
from AMs to DCs, indicating that DCs, AMs and epithelial cells essentially seem to form 
a network of cellular interaction [79]. 
Once these professional phagocytes have internalized particle matter, the cells are 
able to leave the alveolar space and transport the particle cargo out of the lungs. The 
actual clearance, i.e. the removal of the particle-loaded AMs from the lungs and its 
further processing, is generally a short process (24 - 48h) [63]. The predominant 
clearance pathway from the lungs for AMs with ingested particles is probably via 
transport to the upper airways and the mucociliary escalator [65]. In case of particle 
transfer to DCs clearance probably occurs via the lymph. Redistribution of particles 
among AMs (exocytosis and re-uptake by other AMs) is also possible as a way to 
distribute the particle burden among the AMs [80]. 
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Interestingly, there are some differences among different species, as in mice, hamsters, 
and rats significant higher particle amounts are removed via AM clearance when 
compared to humans, probably a result from anatomical and structural differences 
within the lungs [81]. Nevertheless, to date, it is not yet fully understood how AMs 
find their way out of the lungs. 
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4.  Aim of the Work 
The main motivation of this thesis was the fact that there is still very little known to 
date about the ongoing bio-nano interactions after nanoparticle deposition in the 
peripheral lungs. Whereas other research groups in this field mainly focus their 
activities on the effects nanoparticles exhibit on the biophysical functions of PS, we 
decided to investigate how the interactions of nanoparticles with components of the 
PS system actually alter the particle properties, and consequently which role such 
alterations play in the subsequent cellular responses. Regarding possible biological 
effects, we concentrated our studies on clearance by AMs as the most important 
pathway for particle clearance from the deep lungs. To date, no study has been 
performed to investigate this topic for nanoparticles. Therefore, the major aims of this 
thesis were: 
 
1) To evaluate isolations of whole native surfactant and surfactant protein A (SP-A) 
as suitable in vitro models to study bio-nano interactions in the lungs (chapter 5). 
2) To point out the relevance of surfactant proteins for bio-nano interactions in the 
lungs by comparison of the most prevailing SP-A to albumin regarding binding to 
nanoparticles, and the potential of these proteins to trigger AM uptake for 
different kinds of nanoparticles (chapter 6 and 7). 
3) To compare SP-A and SP-D as immuno-relevant surfactant proteins regarding their 
binding to nanoparticles with differences in surface charge and hydrophobicity, as 
well as how they affect AM uptake of these nanoparticles (chapter 8). 
4) To study the influence of surfactant lipids on surfactant protein – mediated AM 
clearance of different nanoparticles (chapter 8). 
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5.  Isolation and Characterization of 
Native Surfactant and Surfactant 
Protein A 
 
 
 
 
 
 
 
 
 
 
Isolation methods presented in this chapter were acquired in collaboration with the laboratories 
of Jesús Pérez-Gil and Cristina Casals during a two months research stay at the Department of 
Biochemistry and Molecular Biology I at Complutense University Madrid. Described procedures 
were performed both in Madrid (Surfactant protein A) and in Saarbrücken (Native surfactant). 
Mass spectrometric analyses were performed in collaboration with Jennifer Herrmann and Prof. 
Rolf Müller from Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarland 
University. 
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5.1.  Introduction 
A crucial prerequisite to bio-nano interactions is access to relevant biological material. 
To study interactions of nanoparticles with plasma constituents in vitro, scientist can 
easily obtain blood plasma from various sources and species, including all relevant 
components necessary to closely mimic the situation nanoparticles would encounter 
in vivo after reaching the blood circulation. With respect to suitable biological models 
of pulmonary surfactant, however, one is confronted with several problems and 
limitations. 
Pulmonary surfactant (PS) is situated at the air-liquid interface and covers the 
epithelium of the lungs as a continuous layer from the alveolar region to the 
conducting airways [5]. Unfortunately, in contrast to the blood circulation, which can 
be relatively easy accessed e.g. by puncturing blood vessels, it is not possible to 
directly extract PS due to the complex anatomy of the lungs. The most often used 
method to obtain PS – rich fluid is bronchoalveolar lavage (BAL), during which the 
lungs are flushed with saline buffers. Human material of this kind can principally be 
obtained during bronchoscopy of patients, although the resulting quantities are very 
limited and ethic concerns have to be clarified. Therefore, whole animal lungs from 
slaughtering are an often-used source for lavages from which PS can be obtained in 
reasonable quantities. However, lung lavage with large buffer volumes means that the 
biological material of interest is highly diluted and eventually altered in its 
composition. Furthrmore, the lavage fluid needs to be purified in extensive procedures 
in order to remove contaminations from mucus or blood, and to isolate surfactant-rich 
membranes. A well-established procedure for this purpose is ultracentrifugation with 
subsequent gradient centrifugation [35]. However, numerous individual lungs need to 
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be treated to obtain useful amount of PS. The maximally complex PS composition that 
can be isolated is native surfactant (NS), sometimes also referred to as natural 
surfactant. NS contains all physiologically relevant surfactant lipid species and the 
hydrophobic SP-B and SP-C, as well as the hydrophilic SP-A [35, 82]. SP-D, however, 
cannot be isolated along with NS [82]. 
Using NS as raw material, it is further possible to isolate the lipophilic components by 
extraction with chloroform / methanol. As lipid extracts (LE) are biophysically active, 
such preparations obtained from various animal sources have been studied intensively 
in the past regarding their application to treat respiratory distress syndrom (RDS) [82-
84]. Due to their commercial availability, preparations such as Curosurf®, Survanta® 
or Alveofact® were frequently used as in vitro models for PS [51, 59, 85, 86]. However, 
LE formulations generally have the disadvantage, that they lack the immunologically 
relevant SP-A, and are therefore only of limited relevance with respect to the 
physiological situation [82]. 
One major aim of this thesis was to investigate the role of the predominant SP-A with 
respect to nanoparticle uptake by AMs. Therefore, NS isolated from porcine lungs was 
chosen as a most complex PS in vitro model, containing SP-A and physiologically 
relevant lipids. For studies on SP-A as a single protein, human SP-A was isolated from 
BAL of patients suffering alveolar proteinosis (AP); a disease with pathologically 
elevated surfactant secretion and therefore SP-A in the alveolar lining fluid (ALF) [87]. 
AP patients periodically undergo BAL as a therapeutic procedure to physically remove 
access material, which can be preserved to isolate SP-A in useful quantities. 
In this chapter, the isolation procedures and methods for characterization of NS and 
SP-A are described.  
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5.2.  Materials and Methods 
5.2.1. Isolation of Porcine Native Surfactant (NS) 
NS from adult pig lungs was obtained as previously described [88]. Porcine lungs were 
obtained from a local slaughterhouse and immediately transported to the laboratories 
on ice. A BAL was performed by repeated instillation, massage removal of in total 
approximately 1.5 l NaCl – buffer (0.9% w/v) per lung. Subsequently, the lavage fluid 
was centrifuged at 1,000 x g for 5 min at 4°C (Hettich Centrifuge 30 RF, Tuttlingen, 
Germany) to remove cellular debris. Then, cell-free BAL was centrifuged stepwise at 
100,000 x g for 2 h at 4°C (Optima L 90 K ultracentrifuge, Beckman Coulter, Krefeld, 
Germany) to obtain large surfactant aggregates in the resulting pellet. PS was 
subsequently purified from blood components by performing a sodium bromide 
(NaBr) density-gradient centrifugation. Briefly, pellets were homogenized in potter 
with 16% NaBr solution (w/v) to a final volume of 24 ml. This suspension was divided 
to 6 tubes and each tube was covered consecutively with 6 ml 13% NaBr solution and 
2.5 ml 0.9% NaCl solution. The tubes were centrifuged at 116,000 x g for 2 h at 4°C 
(Beckman Coulter) and the resulting surfactant pellet was carefully removed and 
resuspended in 3 ml NaCl – buffer. Aliquots of NS were immediately used or stored at -
20°C. 
5.2.2. Isolation of Human Surfactant Protein A (SP-A) 
Human SP-A from BAL of patients with alveolar proteinosis (AP-BAL) was isolated in 
collaboration with Cristina Casals according to the protocol by Ruano et al. [89]. 
Briefly, 2 ml of cell-free AP-BAL were homogenized in Tris-NaCl – buffer (25 mM Tris, 
150 mM NaCl, pH 7.4) in a potter to a final volume of 25 ml and subsequently 
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centrifuged at 100,000 x g for 1 h at 4°C (Beckman Coulter). The resulting pellet was 
homogenized again in a potter with 0.9% NaCl – buffer (w/v) to a volume of 20 ml. 
After determination of total protein concentration as described in 5.2.3, the proteins 
were precipitated by dropwise addition of the resuspended lavage fluid to butanol (30 
ml butanol per mg protein) under stirring. After 30 min stirring, the butanol solution 
was centrifuged in portions at 5,000 x g for 30 min at 15°C (Hettich Centrifuge 30 RF), 
until the precipitate was concentrated. The pellets were dried under nitrogen until 
complete evaporation of the organic solvent. Next, the protein pellets were 
homogenized in OGP – buffer (20 mM octyl-β-D-glucopyranoside, 10 mM HEPES, 150 
mM NaCl, pH 7.4) to extract SP-A. After centrifugation of the extract at 100,000 x g for 
30 min at 15°C (Beckman Coulter), the resulting pellet was homogenized in 3 ml Tris – 
buffer (5 mM Tris, pH 7.4) and dialyzed against Tris – buffer for 24 h to remove traces 
of OGP. Finally, the dialyzed protein was centrifuged at 100,000 x g for 30 min at 4°C 
(Beckman Coulter) and the supernatant, containing SP-D, was collected and stored at -
20°C until usage. 
5.2.3. Protein Determination 
Total protein concentration of NS or SP-A was determined using a BCA (bicinchoninic 
acic) assay kit (Sigma) according to the manufacturers manual. Briefly, 25 µl of sample 
were mixed with 200 µl of BCA reagent solution (reagent A: bicinchoninic acid, sodium 
carbonate, sodium tatrate, sodium bicarbonate in 0.1 N sodium hydroxide; reagent B: 
4%  cooper (II) sulfate pentahydrate (w/v); ratio A / B 50:1) in a 96 well plate (Greiner). 
Bovine serum albumin (BSA, Sigma) was used as protein standard at a concentration of 
0.1 – 1 mg/ml. After incubation for 30 min at 37°C, UV absorption of the resulting 
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complex was measured at 562 nm using an Infinite 200 M multimode microplate 
reader (Tecan, GmbH, Crailsheim, Germany). 
5.2.4. Phosphorus Assay 
Total NS phospholipids were determined by phosphorus analysis as described by 
Rouser et al. [90]. Briefly, samples and standards (KH2PO4 in MQ-water; 0.0037, 0.015, 
0.026, 0.037, 0.092, 0.147 µM) were dried in glass tubes on a sandbath. After addition 
of 450 µl perchloric acid, tubes were incubated on the sandbath at 250°C for 30 min. 
After cooling the tubes to RT, 3.5 ml of MQ-water, 500 µl ammonium molybdate (2.5 % 
w/v) and 500 µl Ascorbic acid (10% w/v) were added to each tube and vortexed. After 
incubation in a waterbath at 100°C for 7 min, the reaction was stopped by placing the 
tubes on ice. Absorbance was measured at 820 nm using an Infinite 200 M multimode 
microplate reader (Tecan). Total phosphorus determination was standardized to 
dipalmitoyl-phosphatidylcholine (DPPC, 734.04 g/mol). 
5.2.5. Western Blotting 
15 µl of NS or SP-A were added to 15 µl SDS-PAGE sample buffer (2-fold concentrated; 
25% (w/v) Glycerol, 60 mM Tris-HCl pH 6.8, 2% (w/v) SDS (Serva, Heidelberg, 
Germany), 0.1% (w/v) Bromophenol Blue (Merck), 5% (v/v) β-mercaptoethanol in MQ-
water). Samples were heated for 5 min at 95°C. Spectra Multicolor Broad range protein 
ladder (10-260 kD; Fermentas, St.Leon-Rot, Germany) was used as molecular weight 
marker. Samples were run in a Mini-Protean TetraCell (BioRad, Munich, Germany) at 
130 V on 12% SDS-polyacrylamide gels. After electrophoresis, proteins were 
transferred to nitrocellulose membrane (Whatman, Maidstone, UK) in a Mini Trans-
Blot Electrophoretic Transfer cell (BioRad) for 90 min at 300 mV. After protein transfer, 
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the blot was blocked for 90 min in blocking buffer (5% non fat milk, 0.1% Tween 80, 
150 mM NaCl, 20 mM Tris-HCl, pH 7.5) and incubated with polyclonal rabbit anti 
human SP-A antibody (1:5000 in blocking buffer; Millipore AB3420) for 12 h at 4°C. 
Subsequently, the blot was treated for 90 min at RT with polyclonal goat anti-rabbit 
alkaline phosphatase conjugate (1:1000 in blocking buffer), followed by staining with 
NBT/BCIP (Roche Diagnostics, Mannheim, Germany). 
5.2.6. MALDI-ToF Mass Spectrometry 
For matrix-assisted laser desorption ionization time-of-flight mass spectrometric 
analysis (MALDI ToF MS), NS was separated by SDS-PAGE under same conditions as 
Western Blotting. After electrophoresis, proteins bands were visualized using PageBlue 
colloidal Coomassie staining solution (Fermentas, St.Leon-Rot, Germany). Protein of 
interest (34 kD band) was excised from the gel automatically using SpotPicker (GE 
Healthcare, Munich, Germany). The slices were then washed with MQ-water (MilliQ- 
Synthesis system, Millipore Corporation, Billerica, MA, USA) and destained with a 1:1 
mixture of 40 mM ammonium bicarbonate and acetonitrile (ACN). After 15 min 
incubation with 100% ACN gel plugs were completely dried and finally rehydrated in a 
minimal volume of 40 mM ammonium bicarbonate containing 25 ng/ml trypsin and 
incubated overnight at 37°C. The in-gel digests were concentrated and desalted using 
ZipTipC18 (Millipore Corporation, Billerica, MA, USA) by elution with 50% (v/v) ACN 
and 0.1% (v/v) trifluoroacetic acid (TFA). Aliquots of peptide solution (0.7 µl) prepared 
from protein spots were mixed with 0.4 µl of α-Cyano-4-hydroxy cinnammic acid 
(CCA, 5 mg/ml in 50% (v/v) ACN and 0.1% (v/v) TFA) on a stainless steel target using the 
dried droplet method [91]. Selected peptides of PMF obtained by MALDI-MS in 
reflector mode were further fragmented by MALDI-PSD using a 4800 MALDI 
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TOF/TOF™ Analyzer (Applied Biosystems, Carlsbad, CA, USA). Peptide mass standards 
(Applied Biosystems) were used for internal calibration of the mass spectra. 
5.2.7. Dynamic Light Scattering 
To determine the presence of protein aggregates, isolated SP-A (60 µg/ml) was 
measured in Tris - (5 mM, pH 7.4) or Tris-NaCl – buffer (5 mM Tris, 150 mM NaCl, pH 
7.4) using dynamic light scattering (DLS). Measurements were performed after 
equilibration for 3 min at 25°C in a ZEN 2112 low volume quartz cuvette using a 
Zetasizer Nano-ZS (Malvern). 
5.2.8. SP-A Self-Aggregation Assay  
The biological activity of isolated SP-A was assayed by testing its ability to self-
associate in the presence of calcium as described by [92]. Briefly, absorbance of 400 µl 
SP-A (50 µg/ml in 5 mM Tris – buffer, pH 7.4) was measured at 360 nm over 30 min at 
25°C using a Perkin Elmer Lambda 35 UV/Vis spectrometer (Perkin Elmer, Rodgau, 
Germany). After 5 min, 1 µl of a 2 M calcium chloride solution was added, the samples 
stirred and measured for the remaining 25 min. 
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5.3.  Results and Discussion 
5.3.1. Isolation and Characterization of Native Surfactant (NS) 
The last step during the isolation of NS is a gradient centrifugation, which – if 
conducted successfully – resulted in a separation of blood components from the 
surfactant-rich membranes, that concentrate on top of the NaBr-phase as a whitish 
cake-like pellet (Figure 5.1). 
 
Figure 5.1. Sample After Sodium Bromide Gradient Centrifugation. 
 
After careful removal from the tubes (Figure 5.1), the surfactant pellets were united 
and characterized in terms of protein and phosphorous concentration. In average, 
approximately 0.5 ml NS per liter BAL fluid could be isolated with total protein 
concentrations ranging between 4 – 6 mg/ml and 20 – 30 mg/ml total phosphorous. 
Hence, the ratio of protein-to-lipid for NS used in the conducted studies was 
approximately between 1:3.3 to 1:7.5, depicting some variations compared to the 
generally accepted ratio of 1:9 (protein-to-lipid) as obtained from BAL analysis [34]. 
Such deviations could derive from contaminations with proteins present in the ALF, 
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but physiologically not associated with surfactant membranes. Likewise, individual 
differences in lung quality due to tissue damages during the slaughter process or 
pathological alterations might be responsible for variations in blood contamination of 
BAL fluid. Furthermore, during purification of NS only the heavy subfractions 
containing large lamellar structures are isolated, whereas a small aggregate fraction, 
also containing lipids, is lost after ultracentrifugation [93]. This partial loose of 
surfactant material could be another explanation why an altered protein-to-lipid ratio 
was obtained with NS. 
Furthermore, presence of SP-A in NS was tested using Western blotting and MALDI ToF 
mass spectrometry. A representative immuno blot and gel image are shown in Figure 
5.2. 
 
 
Figure 5.2. Western Blotting and SDS-PAGE Analysis of Porcine NS. 
(A) Western blot of NS using an anti human SP-A antibody (rabbit, 1:5000). Lane 1: Molecular weight 
marker; lane 2: NS (20 µl; 0.25 mg/mL total protein); lane 3. empty; lane 4. isolated human SP-A (10 µg 
total protein). (B) SDS-PAGE of NS after Coomassie staining. The band indicated by the arrow was excised 
and the protein was subsequently extracted from the gel by trypsin digestion for MALDI ToF analysis. 
Lane 1: Molecular weight marker; lane 2: NS (0.25 mg/mL total protein). 
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A broad signal at 32-38 kD as well as a distinct band at 26 kD resulting from SP-A 
monomers with different degree of glycosylation could be observed for NS sample on 
the blot. Weaver et al. already described a comparable migration behavior of SP-A 
obtained from non AP - BAL in an early study [40]. Human isolated SP-A monomer 
band (control on lane 4 in figure 5.2A) revealed a similar migration behavior. In 
addition, we performed also a mass spectrometric analysis after gel electrophoretic 
separation of NS using SDS-PAGE followed by Coomassie-staining (Figure 5.2B). 
Analysis of the 34 kD band from the Coomassie-stained gel (see arrow in figure 5.2B) 
using MALDI ToF mass spectrometry with subsequent NCBI database searching 
resulted in a protein score of 62 for human pulmonary surfactant-associated protein A 
(GI: 257467612). The coverage of MS-MS-identified human SP-A peptides homologue 
to porcine SP-A was around 27%. While porcine SP-A was not directly found in 
database search, SP-A is reported to be highly conserved among the various species 
studied so far [39, 94]. Therefore we concluded the 34 kD protein band to be identified 
as SP-A monomer. 
5.3.2. Isolation and Characterization of SP-A 
From 2 ml concentrated BAL with a total protein concentration between 20 – 25 
mg/ml, approximately 5 mg SP-A can be isolated. Routinely, the purity of SP-A was 
checked by SDS-PAGE under reducing conditions and identity confirmed by Western 
Blotting (Figure 5.3A and B). On the gel, generally two distinct bands between 26 and 
34 kD as well as at between 52 and 72 kD can be seen, resulting from SP-A monomers 
and dimers, respectively, indicating that the absence of other protein species. The fact 
that dimer bands can be observed even under reducing conditions is known for SP-A 
from AP patients, which however is not fully clarified [87, 95]. 
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Figure 5.3. SDS-PAGE Analysis and Western Blotting of Isolated SP-A. 
(A) Representative Coomassie-stained SDS-PAGE gel of human SP-A under reducing conditions. Lane 1: 
Molecular weight marker; lane 2: isolated human SP-A (10 µg protein). (B) Western blot of human SP-A 
under reducing conditions using an anti human SP-A antibody (rabbit, 1:5000). Lane 1: Molecular weight 
marker; lane 2: isolated human SP-A (1 µg total protein). 
 
Besides SDS-PAGE, identity of SP-A and absence of protein aggregates was analyzed by 
means of DLS (Figure 5.4). From transmission election microscopy it is known that 
native SP-A has a radius of about 20 nm [96]. However, in aqueous conditions the 
hydrodynamic diameter of SP-A is approximately 30 nm as seen from the number 
based size distribution in Figure 5.4A. Presence of SP-A aggregates results in 
appearance of peaks between 400 and 1000 nm (Figure 5.4B). 
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Figure 5.4. Hydrodynamic Diameter of Isolated SP-A as Determined by DLS. 
(A) Analysis of hydrodynamic diameter of isolated human SP-A in Tris – buffer (5 mM, pH 7.4). (B) DLS 
analysis of hydrodynamic diameter of isolated human SP-A in Tris-NaCl – buffer (5 mM Tris, 150 mM 
NaCl, pH 7.4). In presence of NaCl, isolated SP-A forms aggregates as seen by appearance of additional 
peaks with higher sizes. Both graphs are plotted as intensity, volume and number – weighted size 
distributions. 
 
Finally, activity of SP-A was analyzed by measuring the calcium-induced self-
aggregation of the protein (Figure 5.5). The CRD of SP-A has a calcium-binding site and 
it is known, that the presence of increased amounts of calcium to SP-A – SP-A 
interactions, resulting in larger protein aggregates [38, 89]. Besides its ability to 
enhance phagocytosis of bacteria by AM, this phenomenon is also routinely 
investigated to describe the biological activity of SP-A. 
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Figure 5.5. Calcium-Induced Self - Aggregation of SP-A. 
SP-A was measured in Tris – buffer (5 mM, pH 7.4) with and without Ca2+ ions. The ability of SP-A to self-
aggregate was monitored by absorbance measurement at λabs820 nm for 30 min at 25°C. The formation of 
SP-A aggregates causes an increase of turbidity, as observed after 5 min (addition of 1 µl of a 2 M CaCl2-
solution). 
 
 
5.3.3. Discussion of the used models 
BAL from AP patients is commonly exploited to isolate useful quantities of SP-A and 
numerous studies on structure and functions of SP-A have been conducted with 
human protein isolated from this source [89, 97-99]. NS from porcine or bovine 
sources is still frequently used as reference material to evaluate the composition and 
biophysical function of clinical LE preparations [82, 83]. Despite the facts that NS 
isolations lack SP-D and show some variations in final protein and phospholipid 
content (as a matter of fact this applies also to LE preparations), we still believe that 
NS is the most suitable model for PS, as it contains relevant lipids as well as surfactant 
proteins (especially SP-A). Moreover, it is accessible in meaningful quantities. 
In this work, human SP-A and porcine NS were therefore used to study effects of 
surfactant components on nanoparticle uptake by a murine alveolar macrophage cell 
line (MH-S). Although at first this appears as a suboptimal constellation with respect 
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to species differences, it might here be mentioned that SP-A is described as highly 
conserved in human, pig, dog, rat and mouse [39]. Furthermore, cellular effects of SP-A 
have been studied in vitro and in vivo in rodents [59, 100, 101], justifying the usage of 
human or porcine preparations with MH-S cells as mostly presented in this work. 
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6.  Interaction of Metal Oxide 
Nanoparticles with Lung Surfactant 
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6.1.  Introduction 
When nanoparticles come in contact with living systems, they instantly get 
surrounded with various kinds of biomolecules. A fundamental understanding of 
ongoing interactions between nanoparticles and biomolecules, especially proteins, is 
crucial to predict their further biological fate in the human body [27]. The lungs are 
considered as the main entrance portal for nanoparticle to invade the human body due 
to their large absorptive surface area, which is in direct contact to the surrounding 
environment [11, 67]. In this context, especially unintentional inhalation of nano-sized 
materials as a consequence of workplace exposure is of increasing concern, as 
potential long-term damages are hardly predictable [13]. This is a fact contemporary 
society has to face since rash technical application of nanomaterials and usage in 
daily-life products are now reality, whereas scientific research on biological responses 
to nanomaterials appears actually to be still dragged behind this development. 
Therefore, investigations addressing interactions between technically used 
nanomaterials and the lungs are of great importance, in particular with respect to 
possible toxicological consequences. The first biological barrier inhaled particles will 
encounter is pulmonary surfactant (PS). Regarding interactions between components 
of PS and inhaled particles, surfactant protein A (SP-A) is a most interesting candidate 
for such bio-nano interactions due to its important role in the pulmonary host defense 
system [38]. The adsorption of PS components has already been addressed in several 
studies for diesel soot, quartz and kaolin [102] as well as for gold [49], TiO2 and 
polystyrene nanoparticles [47, 103]. However, these studies predominantly 
concentrated on the lipid moiety of PS, and interactions of the immunologically 
relevant SP-A have practically been omitted so far. Furthermore, with the exception of 
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TiO2, quartz and kaolin, those particles are hardly transferable to materials that are 
handled at kiloton scale already, such as for instance metal oxide nanoparticles. 
Therefore, we studied the binding of SP-A from porcine BAL fluid (pBALF) to metal 
oxide nanoparticles that are produced and handled at large scales. 
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6.2.  Materials and Methods 
6.2.1. Preparation of Porcine Broncheoalveolar Lavage Fluid (pBALF) 
pBALF preparation was modified after Taeusch et al. [88]. In short, three porcine lungs 
were lavaged the fluid of all lungs was pooled and centrifuged at 1400 rpm for 4 min 
at 15°C to remove cellular residues. The thus obtained volume of about 2 l of pBALF 
was frozen at -80 °C prior lyophilization using a Christ Alpha 2-4 LSC lyophilization 
device (Christ, Osterode am Harz, Germany) and resupended in 200 ml of MQ-water in 
order to concentrate the proteins. The protein content was determined with BCA-
assay to be 74.03 mg/ml. The presence of SP-A was confirmed by Western blotting and 
Immuno-staining, performed as described later, in comparison with literature [38, 94] 
and a SP-A reference isolated from AP BAL. The pBALF was aliquoted and stored at -80 
°C until use. 
6.2.2. SP-A Adsorption to Metal Oxide Nanoparticles 
Metal oxide nanoparticles (BaSO4, AlOOH, TiO2 (A), TiO2 (B), CeO2 (A), CeO2 (B), CeO2 (C), 
Carbon black; each 148 mg) were dispersed with 2 ml of a 1:10 diluted pBALF solution 
(final protein concentration of 7.4 mg/ml), leading to particle-protein ratio of 10:1. The 
resulting dispersions were stirred at RT for 1 h at 300 rpm and subsequently 
centrifuged at 23,000 g for 45 min at 10°C (Hettich Universal 30 RF). After 
centrifugation, the supernatants were removed, the particle pellets washed 3 times 
with MQ-water and resuspended with 0.5 ml of MQ-water. Supernatants and pellet 
dispersions (each 100 µl, respectively) were mixed with 100 µl of 2-fold concentrated 
sample buffer and denatured for 5 min at 95 °C to for protein desorption. After 
desorption, samples were separated and analyzed as described in section 5.2.5.  
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6.3.  Results and Discussion 
To measure the binding of SP-A onto the metal oxide nanoparticles, samples of both 
the supernatant and the pellet of the previously described adsorption experiment 
were analyzed by SDS-PAGE under reducing conditions, followed by Western blot and 
immuno-staining (Figure 6.1). 
 
 
Figure 6.1. Adsorption of SP-A from pBALF at a Nanoparticle – to - Protein Ratio of 10:1.  
Immuno-blot of SP-A monomer band (between 42 and 34 kD) from supernatant and pellets of 
nanoparticles after conditioning in pBALF. As control (w/o particles), pBALF 1:10 diluted was used. MWSt 
stand for molecular weight standard. Experiments were repeated three times. 
 
TiO2 (A) and BaSO4 showed high SP-A interaction as suggested by a strong SP-A signal 
in the pellet and a weak (TiO2 A) or no (BaSO4) signal in the supernatant. 
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In contrast, binding of SP-A to CeO2 (C) was only weak, as indicated by the fact that the 
strongest signal was found in the supernatant and the weaker signal in the pellet. For 
AlOOH, SP-A was only detected in the pellet, similar as for BaSO4.  
Strongest SP-A binding in pBALF was observed for TiO2 (B), CeO2 (A) and (B) and carbon 
black. For neither of those particles any SP-A signal could be detected in the 
supernatant. For TiO2 (B) and CeO2 (B), similar SP-A adsorption to the nanoparticles 
was observed (intermediate SP-A signal in the pellet). Only a very weak SP-A signal 
was found for CeO2 (A) pellet, whereas carbon black revealed no SP-A signal at all. 
Notably, the SP-A signals of the pellets compared to the supernatants were not 
correlating for TiO2 (B), CeO2 (A) and (B) and for carbon black. We speculate that an 
extremely strong binding of SP-A to the surface of those types of nanoparticles, even 
resisting the conditions of the desorption protocol used in this study, might be the 
reason for this observation. 
The detailed physicochemical interactions underlying the binding of SP-A to these 
particles could not be investigated in this study. However, as hydrophobic interactions 
are described as the main driving force for particle protein interactions [19], it might 
be speculated such interactions also dominate the here observed SP-A adsorption. 
Especially carbon black is a very hydrophobic material, showing here actually such a 
strong binding of SP-A, that the proteins could not be eluted from the particles for 
which reason no protein signal could be detected on the immuno-blot. 
Nevertheless, by comparing SP-A bindung to the different nanomaterials in this study, 
we could observe striking differences, even for nanoparticles made of the same 
material (e.g. CeO2 (A) versus (B) or (C); TiO2 (A) versus (B)). 
Therefore, there are convincing reasons to assume that the binding of SP-A, and 
probably other lung surfactant proteins as well, will alter the surface of nanoparticles, 
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resulting in particle-protein complexes, possibly causing different reactions towards 
cells compared to the pristine particulate matter. 
 
 
6.4.  Conclusion 
In this study, differences in the interaction of metal oxide nanoparticles with 
physiologically relevant SP-A were demonstrated. However, although the here tested 
particulate materials are already used widely in technical processes and products, and 
therefore of high relevance, these systems lacked important information regarding 
their exact chemical composition, and some were moreover partly hard to 
characterize, in particular in terms of particle size and surface charge in aqueous 
suspensions. 
For the subsequent investigation, we therefore decided to use commercially available 
and well-characterized magnetite – based nanoparticles (mNP) as model system. 
These mNPs were available with different surface modifications, allowing to study 
interactions of PS components nano-sized particles and relevant cellular effects in 
material-dependent manner, as well as in function of nanoparticle surface charge and 
hydrophobicity. 
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7.  Uptake of nanoparticles by alveolar 
macrophages is triggered by surfactant 
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7.1.  Abstract 
Understanding the bio-nano interactions in the lungs upon the inhalation of 
nanoparticles is a major challenge in both pulmonary Nanomedicine and 
Nanotoxicology. In order to study the effect of surface properties on protein 
adsorption, we used magnetite nanoparticles (110 – 160 nm in diameter) coated with 
different polymers (starch, carboxymethyldextran, chitosan, poly-maleic-oleic acid, 
phosphatidylcholine). For these five different nanomaterials, we could demonstrate a 
significantly different adsorption of surfactant protein A (SP-A), the prevailing protein 
in pulmonary surfactant (PS), compared to albumin, the prevailing protein in plasma. 
As a consequence, cellular binding and uptake of nanoparticles by alveolar 
macrophages (AM) was increased for nanoparticles with adsorbed SP-A, whereas 
adsorption of albumin led to a significant decrease. This study provides first evidence 
that after inhalation of nanoparticles, where the first encountered body liquid is the 
alveolar lining fluid (ALF), a different corona and thus different biological behavior 
may result than after direct administration to the blood stream. 
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7.2.  Introduction 
Interactions of nanomaterials with complex biological molecules (bio-nano 
interactions) are most definitely the high priority topic to ensure safety and 
applicability of nanotechnology [27], and are therefore highly important in both 
Nanomedicine and Nanotoxicology. Especially the lungs with a large surface area (140 
m2) are considered to be the organ with highest relevance in terms of nanoparticle 
exposure [1, 67]. 
Therefore, various studies in the past addressed nanoparticle inhalation, and 
demonstrated the possibility of deposition in the peripheral lungs. Furthermore, 
biodistribution of inhaled nanoparticles is topic of several in vivo studies, making clear 
that the lungs can also be an entrance port for nanoparticles to the systemic 
circulation and secondary organs [104-106]. 
However, there is still a lot to be understood about the actual intermediate steps 
between deposition and biodistribution, that is: what happens after landing of 
nanoparticles in the respiratory region, and how do they interact with the air-blood 
barrier? The first biological surface encountered by nanoparticles deposited on the 
alveolar epithelium of the peripheral lungs is PS, an integral part of an ultra thin liquid 
layer known as the ALF. PS is a complex mixture constituted by about 90% lipids 
(which are mainly phospholipids) and 5-10% proteins [34]. 
Interactions between inhaled nanoparticles and the PS system have already been the 
subject of various studies in the last years. Schürch et al. showed that particles are 
displaced into the ALF upon first contact with PS [46], and can hereby interfere with 
the structural integrity of this complex system. Therefore, recent work mainly focused 
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on the influence such nanoparticles exhibit on biophysical functions of the PS film by 
interacting with its lipid components [47-49, 86]. 
However, once a nanoparticle is submersed in PS, biomolecules - especially surfactant 
proteins - might selectively adsorb to the particle surface. They can then constitute the 
actual interface of the particles interacting with cells, and may thereby determine the 
further biological fate of the nanoparticles. Dawson et al. described this phenomenon 
recently as the protein-corona theory in conjunction with plasma protein adsorption 
to nanoparticles in the blood stream [27] [26]. Protein adsorption and also the identity 
of the binding proteins seems to be mainly ruled by the physicochemical properties of 
the nanomaterials [19]. A prominent example demonstrating how the biological fate 
of nanoparticles is influenced by adsorbed proteins is a study from Kreuter et al. [107]. 
They showed that the preferential adsorption of apolipoproteins B or E to polysorbate 
80-coated poly(butyl-cyanoacrylate) nanoparticles in the blood resulted in a receptor-
mediated uptake into brain capillary endothelial cells, possibly enabling the 
nanoparticles thereby to enter the brain tissue. Apolipoprotein B or E most probably 
function here like unexpected second messengers for nanoparticles. 
With respect to nanoparticles in the deep lungs, our hypothesis is that there is a 
comparable scenario as in the blood stream. A fundamental understanding of such bio-
nano interactions is a major challenge in pulmonary Nanomedicine, actually an 
indispensable prerequisite to be investigated in terms of Nanosafety. Protein 
adsorption to nanoparticles in the peripheral lungs is a crucial intermediate effect 
between nanoparticle deposition on the one hand, and particle clearance, 
translocation or also toxic effects on the other hand. Astonishingly, however, this 
aspect has only been marginally addressed so far. PS contains about 5-10% protein. 
Among this protein moiety, four pulmonary surfactant-associated proteins (SP) are 
Chapter 7: SP-A triggers Nanoparticle Uptake by Alveolar Macrophages 
 
 50 
known: SP-A, -B, -C and -D. The hydrophobic proteins SP-B and SP-C are highly 
associated with lipids and mainly contribute to the biophysical functions of PS by 
reducing the surface tension at the air-liquid interface and thereby prevent the alveoli 
from collapsing [37, 108]. SP-A and SP-D play an important role in the host defense 
system of the lungs [43]. 
Especially the most prevailing protein, SP-A, is likely to play a key role in adsorption to 
nanoparticles and related biological effects. With its lectin domain (also referred to as 
carbohydrate recognition domain, CRD), SP-A is able to bind a variety of biological 
patterns present on the surface of bacteria, viruses, yeast and fungi [43]. Hereby, it acts 
as a broad-spectrum pulmonary opsonin, which greatly influences the activity of AMs 
and other cells in the alveolar tissue [109, 110]. 
In this study, we used magnetite nanoparticles (mNP) with different surface properties 
to investigate the material-dependent binding of SP-A. To explore the resulting 
biological effects of surfactant protein adsorption, we studied binding and uptake by 
AMs using flow cytometry analysis and confocal laser scanning microscopy (CLSM). 
For comparison, bovine serum albumin (BSA) was studied as the prevailing protein in 
plasma. 
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7.3.  Materials and Methods 
7.3.1. Particles and Reagents 
Magnetic fluorescent nanoparticles (mNP; magnetite core with different polymer 
coatings; diameter given by manufacturer 150 nm; stock solution of 25 mg/ml, 
approximately 2.2*1014 mNPs per g) were purchased from chemicell GmbH (Berlin, 
Germany). All tested mNPs were ordered with a yellow-green fluorescent label (Ex: 
476 nm, Em: 490 and 515 nm; Lumogen® F Yellow 083, BASF, Germany). Native 
surfactant (NS) from adult pig lungs was purified as described in chapter 5.2.1. Human 
SP-A was isolated from BAL of patients with alveolar proteinosis as described in 
chapter 5.2.2. Cell culture reagents were obtained from Gibco (Invitrogen, Carlsbad, 
CA, USA), unless indicated otherwise. All other chemicals and reagents were purchased 
from Sigma (Munich, Germany) if no other source is stated. 
7.3.2. Dynamic Light Scattering (DLS) and Zeta-Potential 
All tested mNPs were characterized in MQ-water in terms of particle diameter and 
zeta-potential prior use. Volume-based size distributions of mNPs were determined by 
means of DLS using a Zetasizer Nano-ZS (Malvern Instruments, Malvern, UK). For each 
measurement, the sample was diluted to a concentration of 25 µg/ml in MQ-water. 
Furthermore, to study the effect of RPMI, BSA, SP-A on the nanoparticle size 
distributions, 20 µl mNPs (0.5 mg/ml) were incubated for 10 min at RT in 180 µl of 
either RPMI w/o foetal calf serum (FCS) only, RPMI + BSA (1 mg/ml) or RPMI + SP-A (10 
µg/ml). Samples were diluted to 800 µl with MQ-water and measured three times 
using a Zetasizer Nano-ZS (Malvern). 
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The zeta-potential of mNPs was measured with the same apparatus by Laser Doppler 
velocimetry using folded capillary cells. To study the effect of BSA and SP-A on the 
mNP’s zeta-potential, 100 µl mNPs (0.25 mg/ml) were added to 600 µl 10-fold diluted 
Tris-NaCl (pH 7.4) and then mixed with 5 µl of BSA (2 mg/ml) or 6 µl SP-A (1.76 
mg/ml) and incubated for 5 min at RT (final protein concentration ~0.002% (w/v)). All 
measurements were performed at 25°C. Data were collected and analyzed using the 
Zetasizer Software (version 6.01) from Malvern. 
7.3.3. Scanning Electron Microscopy (SEM) 
Samples were prepared by deposition of mNP suspensions on cleaned silicon wafers 
followed by air drying and subsequent gold coating of the surfaces (Auto Fine Coater 
JSC 1300, Jeol, Akishima, Japan) as described elsewhere [111]. Particles were imaged 
with a JSM 7001F Field Emission SEM (Jeol, Akishima, Japan) under high vacuum 
conditions and room temperature. Accelerating voltage was 20 kV with a focal 
distance of 10 mm. 
7.3.4. Protein Binding Assay 
To study the adsorption of BSA, isolated SP-A or SP-A from NS, 20 µl mNPs were 
incubated in 180 µl protein solution of 100 µg/ml BSA, 50 µg/ml isolated SP-A or 0.5 
mg/ml NS (total protein, corresponding to approximately 0.4 mg/ml SP-A as 
determined by densitometry), respectively, in NaCl-Tris-HCl – buffer. Particle stock 
dispersions (25 mg/ml) were diluted with MQ-water to a 10-fold concentration, 
resulting in a final mNP-to-total protein of approximately 2 to 1 (w/w). mNP 
concentrations were adjusted to achieve the same total surface area represented by 
mNPs for each polymer coating, assuming non-agglomerated particles in spherical 
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shape under consideration of respective particle diameters in MQ-water as 
determined by DLS. After 20 min incubation at 37°C, mNPs were separated from 
unbound material (unbound proteins) using a M2 magnet separator (Bilatec, 
Viernheim, Germany). Proteins of interest were desorbed from mNPs under 
denaturing conditions (bound proteins). Samples were analyzed under reducing 
conditions on 12% SDS-polyacrylamide gels. After electrophoretic protein separation, 
gels were fixed and stained with colloidal Coomassie (PageBlue, Fermentas, St.Leon-
Rot, Germany). Intensity of the respective monomer band was determined by means 
of densitometry using Image J (Version 1.41o). From band intensity, protein 
concentration was determined and expressed as bound protein in percent of control 
(respective protein solution without mNPs). See supporting information for protocol 
details and representative gel image. 
7.3.5. Alveolar Macrophage Cell Culture 
Murine AMs (MH-S; ATCC CRL-2019, Wesel, Germany) were grown under adherent 
conditions in RPMI 1640 with L-glutamine cell culture medium (RPMI; PAA, Pasching, 
Austria) supplemented with 10% (v/v) FCS (PAN Biotech, Aidenbach, Germany), 1% 
(v/v) HEPES, 25 mM D-glucose, 18 mM sodium bicarbonate (Merck), 1 mM sodium 
pyruvate and 0.05 mM β-mercaptoethanol. Cells were incubated at 37°C under 
humidified 5% CO2 atmosphere. Microscopic images were recorded using an Axiovert 
25 microscope (Zeiss, Jena, Germany), equipped with a Moticam 2300 digital camera 
(Motic GmbH, Wetzlar, Germany). A representative image of MH-S cells in culture is 
shown in Figure 7.1. 
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Figure 7.1. Murine AMs (MH-S) in Culture. 
Cells are shown in 10-fold (left) and 20-fold (right) magnification. 
 
7.3.6. Interaction of mNPs with AMs 
MH-S (2 x 105 cells per well) were seeded in 24-well plates (Greiner Bio-One, 
Frickenhausen, Germany) and cultivated for 2 days in supplemented RPMI. Before each 
experiment, MH-S were washed with PBS (Dulbecco’s Phosphate Buffered Saline; 
Sigma), equilibrated for 30 min in 200 µl supplemented RPMI without FCS (RPMI w/o 
FCS) at 37°C and exposed to test formulations for 90 min at 37°C under gently shaking 
conditions. Test formulations were prepared as follows: 20 µl aqueous mNP 
suspension (20-fold) were incubated for 20 min at 37°C in 180 µl RPMI w/o FCS 
supplemented with either BSA (1 mg/ml) or isolated SP-A (5 µg/ml). As control, mNP 
were pre-incubated in RPMI w/o FCS without any further added protein (mNP only). 
Pre-incubated mNP formulations were then added to MH-S cells resulting in finally 1 x 
1010 mNP per ml. After 90 min incubation, cells were washed twice with PBS, treated 
with 150 µl Trypsin-EDTA and resuspended in 350 µl RPMI with FCS. mNP - MH-S 
association was determined using flow cytometry (FACSCalibur, Becton Dickinson, 
Franklin Lakes, NJ, USA). Five thousand events were collected in a gate based on 
forward and side scatter using CellQuest software (Version 3.3, Becton Dickinson). The 
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increase of fluorescence in the Fl-1 - channel compared to MH-S without mNPs was 
measured as indicator for mNP - MH-S interaction (compare Figure 7.2). Data were 
analyzed using the software FlowJow software (Version 8.8.6; Tree Star Inc., Ashland, 
OR, USA). 
 
Figure 7.2. Flow Cytometry – Based Analysis of mNP Interaction with MH-S Cells.  
Percent of cells with FL-1 > 101 (encircled number) were considered as positive cells due to interaction 
with mNPs. MH-S cells only were measured as control and subtracted as background from values 
obtained with mNPs. 
 
7.3.7. Visualization and Quantification of Particle Association and Uptake 
The interaction of mNPs and MH-S was visualized by means of CLSM. MH-S (2 x 105 
per well) were seeded in 24-well imaging plates (zell-kontakt®, Nörten-Hardenberg, 
Germany) and cultivated for 2 days. Experiments were performed in analogy to flow 
cytometry-based assays (see above). After 90 min incubation at 37°C under gentle 
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shaking, cells were washed twice with PBS and subsequently incubated for 10 min 
with 400 µl rhodamine riccinus communis agglutinin I (RRCA; 1:400 in PBS; Vector 
Laboratories, Burlingame, CA, USA) at 37°C for membrane staining. After two times 
washing with PBS, cells were fixed with formaldehyde (4% (v/v) in PBS) for 10 min, 
and washed again twice with PBS. A Zeiss LSM 510 with META detector (Carl Zeiss AG, 
Oberkochen, Germany), equipped with a 63x oil immersion objective (NA 1.3) was 
used to visualize samples to analyze samples in z-direction. To discriminate between 
internalized and cell-adherent mNPs, we conducted a quantitative image analysis 
using micrographs recorded in the equatorial plane of the cells (compare Figure 7.3). 
 
 
Figure 7.3. CLSM – Based Differentiation Between Adherent and Internalized mNPs. 
Optical cross sections of cells in z-direction were recorded and images of the cellular equatorial planes 
were recorded for relative particle quantification per cell. 
Total number of mNPs associated with cells was counted and related to the number of mNPs inside 
cellular membranes (expressed as percent internalized mNPs). 
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Cells and particles were manually counted for each micrograph, and mNPs located 
inside the membrane boundary were considered as internalized. mNP number inside 
membrane boundary was counted from at least six images of equatorial plane per 
experiment and expressed as percent internalized particles by MH-S cells. All images 
were analyzed using the software Volocity LE (Version 5.3.1; Perkin Elmer, Waltham, 
MA, USA). 
7.3.8. Statistical analysis 
Differences in SP-A adsorption study and the flow cytometry - based MH-S interaction 
studies were analyzed using One-way ANOVA with Newman-Keuls posthoc tests. All 
other statistical analysis was assessed by Student‘s t-test. For all tests, p < 0.05 was 
considered to indicate a statistically significant difference. All statistical analyses were 
performed using Graphpad Prism 5 software. 
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7.4.  Results 
7.4.1. Particle characterization 
Polymer-coated mNPs were characterized in terms of particle size and surface charge 
using DLS. These measurements revealed a diameter for all mNP modifications 
between approximately 110-160 nm with narrow size distributions (Table 7.1). Zeta-
potential measurements in water resulted in positive values for Chitosan (CH)- and 
Poly-Maleic-Oleic Acid (PMO)- mNPs and negative values for Phosphatidylcholine 
(PL)- and Carboxymethyldextran (CMX)- mNP. Starch (ST)- modified mNPs showed a 
slightly negative zeta-potential. 
 
Table 7.1. Characterization of Used mNPs. 
 
† All samples were independently measured at least three times in MQ-water. Z-average, Poly-dispersity 
index (PdI) and Zeta-potential were determined using a Zetasizer Nano-ZS (Malvern Instruments, 
Malvern, UK), and are displayed as mean ± standard deviation (n=3). 
 
 
Surface modification Z-average (nm)† PdI 
Zeta-potential 
(mV)† 
Starch 
(ST) 131.5 ± 0.9 0.149 ± 0.009 - 4.2 ± 0.2 
Carboxymethyl- 
dextran (CMX) 165.5 ± 1.1 0.092 ± 0.017 - 42.4 ±1.3 
Chitosan (CH) 152.0 ± 1.1 0.137 ± 0.017 23.9 ± 0.7 
Poly-Maleic- 
Oleic Acid (PMO) 107.5 ± 0.9 0.116 ± 0.006 15.1 ± 0.3 
Phosphatidylcholine (PL) 133.4 ± 1.6 0.182 ± 0.001 - 34.5 ± 0.2 
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Furthermore, the mNPs were morphologically characterized using SEM (Figure 7.4). 
This technique confirmed the measured particle diameters from DLS. Additionally, a 
fairly spherical morphology was found, revealing also a multi-domain magnetic core 
composition of the mNPs. The used mNPs featured the same core material but 
different surface properties in a comparable size range, qualifying them as a suitable 
model system to study protein binding as a function of the nanoparticle’s outer surface 
coating. 
 
 
Figure 7.4. SEM Images of Used mNPs with Different Surface Modifications. 
(A) Starch; (B) Carboxymethyldextran; (C) Chitosan; (D) Poly-Maleic-Oleic acid; (E) Phosphatidylcholine. 
A fairly spherical morphology was found, revealing a multi domain magnetic core composition of the 
mNPs due to composition of clustered 20 nm iron oxide particles (based on information given by 
chemicell GmbH, Berlin, Germany). White scale bars indicate a distance of 100 nm. 
 
7.4.2. SP-A and BSA Adsorption to mNPs 
After incubation of mNPs in protein containing physiological media, magnetic 
separation was applied to separate protein-nanoparticle complexes from unbound 
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proteins [112]. Particle-bound proteins were desorbed under denaturing conditions 
and analyzed using SDS-PAGE followed by Coomassie staining (Figure 7.5). 
 
 
Figure 7.5. Representative Coomassie-Stained Gel of SP-A Adsorption from  
SP-A - Containing NS. 
Non-adsorbed (unbound; lane 3, 6, 10, 13, 16), adsorbed (bound; lane 4, 7, 11, 14, 17) and remaining 
mNPs after desorption (pellet; lane 5, 8, 12, 15, 18). Starch (ST); Carboxymethyldextran (CMX); Chitosan 
(CH); Poly-Maleic-Oleic acid (PMO); Phosphatidylcholine (PL). From Coomassie stained gels, the intensity 
of bound SP-A bands (35 kD, see arrow) was estimated using densitometry. Lane 1+9: Molecular weight 
marker; lane 2: NS control. 
 
The amount of nanoparticle-adsorbed protein was determined by densitometry of the 
respective monomer bands in gels. Among the tested mNPs, obvious differences in 
protein binding were observed (Figure 7.6). Some mNPs showed a lower binding than 
others (e.g. CMX- vs. PL-mNPs), demonstrating a material-dependent effect. 
Concerning SP-A, the binding from SP-A-containing NS was always well comparable 
with binding of the isolated protein. 
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Figure 7.6. Protein Adsorption to mNPs After 20 min Incubation in BSA, SP-A or SP-A-
Containing NS as Determined by Densitometry. 
Starch (ST); Carboxymethyldextran (CMX); Chitosan (CH); Poly-Maleic-Oleic acid (PMO); 
Phosphatidylcholine (PL). Data represent mean of at least three independent experiments ± standard 
error. * Indicates the level of significant difference compared to SP-A (p < 0.05). 
 
For all mNPs, however, adsorption of BSA was significantly lower than SP-A. Especially 
in case of PL-mNPs, the different binding of these two proteins was most pronounced, 
being almost five times higher for SP-A compared to BSA. Binding of BSA remained 
here on the same level as for the two low-binding mNPs ST- and CMX-mNPs. 
Accordingly, zeta-potentials of particles with low binding to either SP-A or BSA (ST- 
and CMX-mNPs) were only marginally changed in presence of protein (Table 7.2). 
Whereas, mNPs with high SP-A adsorption (CH-, PMO- and PL-mNP) showed also 
more drastic changes in zeta-potential, compared to respective mNPs in buffer or in 
presence of BSA. 
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Table 7.2. Size and Zeta-Potential of Differently Modified mNPs in Relevant Media. 
 
 
* Peak means of volume based size distributions were determined using a Zetasizer Nano-ZS (Malvern 
Instruments, Malvern, UK), and are displayed as mean ± standard deviation (n=3). 
† For each measurement mNPs were incubated for 10 min at RT in supplemented with either BSA (1 
mg/ml) or RPMI + SP-A (10 µg/ml). 
‡  Zeta-potentials were determined using a Zetasizer Nano-ZS (Malvern Instruments, Malvern, UK), and 
are displayed as mean ± standard deviation (n=3). 
§ Samples were measured after 5 min incubation at 25°C in 10-fold diluted Tris-NaCl (pH 7.4) 
supplemented with either BSA or SP-A (0.002% (w/v) final protein concentration). 
 
7.4.3. Effect of SP-A and BSA on AM Association and Particle Agglomeration 
The effect of SP-A and BSA, respectively, on the cellular binding and uptake of mNPs, 
was studied in an immortalized mouse AM model (MH-S). As the adsorption of 
isolated SP-A and from SP-A-containing NS was not significantly different, we 
Surface modification 
Peak mean of volume-
based size distribution 
[nm] * 
 Zeta potential [mV] ‡ 
+ BSA † + SP-A †  + BSA § +SP-A § 
Starch 
(ST) 139.5±2.0 135.5±0.8  - 3.1 ± 0.3 - 3.7 ± 0.4 
Carboxymethyldextran 
(CMX) 171.4±2.1 170.5±1.1  - 27.3 ± 1.3 - 29.9 ± 1.6 
Chitosan (CH) 696±159 856±188  - 17.6 ± 0.1 - 22.8 ± 1.3 
Poly-Maleic-Oleic Acid 
(PMO) 1057±159 1063±412  - 8.6 ± 0.6 - 15.4 ± 0.2 
Phosphatidylcholine 
(PL) 145.4±7.7 135.2±5.1  -31.8 ± 0.6 - 39.2 ± 1.8 
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subsequently focused the comparison on the isolated proteins only, i.e. SP-A versus 
BSA, using flow cytometry (Figure 7.7). 
 
 
Figure 7.7. Influence of BSA and SP-A on the Association of mNPs with AMs. 
mNPs (1x1010 nanoparticles/ml) were pre-incubated with BSA (1 mg/ml), SP-A (5 µg/ml) and exposed to 
2x105 MH-S cells for 90 min at 37°C. All experiments were carried out in cell culture media free of FCS 
(RPMI w/o FCS), to avoid undesirable interferences of serum proteins with the nanoparticle-protein-
complexes. As control, mNP were pre-incubated in RPMI w/o FCS (mNP only). Percent values of events 
with Fl-1 above 101 of MH-S only control were subtracted from each sample as background. Data 
represent mean ± standard error from at least three experiments. * Indicates a significant difference 
compared to SP-A (p < 0.05). 
 
In case of CH-, PMO- and PL-mNPs, a significantly increased cell association was 
observed for SP-A compared to BSA. In contrast, ST- and CMX-mNPs showed no 
differences in cell association for the two proteins, and remained at rather low levels. 
Surprisingly, when studying mNPs after dispersion in protein-free cell culture medium 
(“mNP only”), comparably high levels of cell interaction as obtained with SP-A were 
observed for CH- and PMO-mNPs. To further address this phenomenon, we 
investigated the mNP size distribution in the same test media, using DLS (Figure 7.8). 
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Figure 7.8. Volume-Based Size Distribution of mNPs in Different Relevant Media. 
For each measurement mNPs were incubated for 10 min at RT in either RPMI w/o FCS, or RPMI 
supplemented with BSA (1 mg/ml) or RPMI + SP-A (10 µg/ml). Data represent mean distribution of three 
measurements. All samples were measured using a Zetasizer Nano-ZS (Malvern). 
 
While ST- and CMX-mNPs maintained colloidal stability in all test media, larger 
agglomerates were observed for CH- and PMO-mNPs when dispersed in either 
protein-containing or protein-free RPMI. In contrast, PL-mNPs, which had previously 
shown high adsorption of SP-A, but low binding of BSA, remained colloidally dispersed 
in each test medium, regardless of its protein content. 
7.4.4. Visualization and quantification of SP-A mediated cellular uptake by AMs 
A major drawback of flow cytometry is the incapability to discriminate between 
internalized and cell adherent mNPs. Due to the fact that these mNP could not be 
further customized for intracellular detection such as propidium iodid tracing [113], 
we chose to address this question by CLSM. Analysis of z-stack series revealed images 
recorded at the cellular equatorial plane as representative cross section for relative 
quantification of uptake (Figure 7.9). 
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Figure 7.9. Z-stack Series of Horizontal Sections of MH-S Cells Exposed to PL-mNPs in 
Presence of SP-A. 
Images were recorded from upper cell surface (A) to cell bottom (I). Micrographs recorded at the cellular 
equatorial plane as displayed in image G (blue box) were used for quantitative image analysis. Scale bars 
indicate a distance of 15 µm. 
 
Moreover, we decided to focus only on the most reactive CH-, PMO- and PL-mNPs to 
study the effect exerted by SP-A versus BSA on the internalization by AMs (Figure 
7.10). 
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Figure 7.10. Influence of SP-A on Internalization of mNPs by AMs. 
Representative images of MH-S cells (membrane in red) exposed to CH-mNPs (A-C), PMO-mNPs (D-F) or 
PL-mNPs (G-I; mNPs in green; 1x1010 nanoparticles/ml; pre-incubated for 20 min at 37°C without protein 
(A,D,G), 1mg/ml BSA (B,E,H) or with 5 µg/mL SP-A (C,F,I)) for 90 min at 37°C are shown. mNPs per cell 
were manually counted, and the nanoparticle number inside membrane boundary (see white arows for 
exemplary mNPs) was counted from at least six images of equatorial plane per experiment and expressed 
as percent internalized particles by MH-S cells (J). Scale bars indicate a distance of 16 µm. Data represent 
mean ± standard error from at least four experiments (BSA two experiments). * Indicates the level of 
significant difference (p < 0.05). 
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Quantitative image analysis revealed that pre-treatment of mNPs with BSA tended to 
decrease internalization for each tested mNP in comparison to protein-free media 
(“mNP only”), while SP-A increased it (Figure 7.10J). The increased uptake under 
influence of SP-A was most pronounced for PL-mNPs, where it even reached statistical 
significance (p < 0.05). SP-A-induced cellular uptake was moreover most pronounced 
for PL-mNPs compared to CH- and PMO-mNPs (p < 0.05). 
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7.5.  Discussion 
Our results indicate, that when nanoparticles make first contact with a protein which 
is highly relevant for the peripheral lung (i.e. SP-A), they experience a different protein 
priming than when they get in contact with a component of the blood stream (BSA). 
Under the assumption they may act like “second messengers”, the proteins adsorbed 
to a nanoparticle in the physiological compartment where it gets in first contact with 
the body – regardless whether intended or accidentally – may be very decisive for the 
subsequent biodistribution and other biological responses. This was exemplified here 
by studying the interaction of nanoparticles with AMs. 
We first could show that for all nanoparticles tested, binding of pulmonary SP-A was 
stronger than that of BSA. Furthermore, some mNP showed lower SP-A binding than 
others, pointing out that the primary surface material of the nanoparticles greatly 
influences the affinity to this protein (Figure 7.6). The mNPs used in this study were 
composed of magnetite cores covered by different polymer shells. The chemical 
properties of these coating materials obviously control which biomolecules will bind 
to the nanoparticles [19]. Such a material-dependent adsorption of SP-A was also 
found in the study described in chapter 6, investigating the binding of SP-A to different 
metal oxide nanomaterials [56]. Morales et al. also concluded that SP-A adsorption to 
Carbon nanotubes was determined by functional groups such as carboxyl or carbonyl 
residues [57]. 
Among the tested different nanoparticles, ST- and CMX-mNPs showed the weakest 
protein binding, going along with no or at most slight changes of zeta-potentials 
(Table 7.2). The hydrophilic nature of these two polymers might be a reasonable 
explanation for significantly lower protein adsorption of these mNPs. 
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For the three strongest SP-A binding mNPs (CH, PMO and PL), the most pronounced 
changes in the zeta-potential were observed after incubation to this protein (Table 
7.2). The more negative values, compared to those measured in buffer or BSA, are well 
explained by the adsorption of SP-A, as this protein is negatively charged at 
physiological pH due to its isoelectric point of pH 4-5 [36]. 
In case of CH-mNPs, protein-particle adsorption probably results from attractive 
electrostatic interactions between SP-A and the positive surface charge of CH-mNPs 
(Table 7.2) at the initial moment of exposition to protein. In addition, hydrogen 
bonding between primary amine- or hydroxyl-groups of chitosan and carbonyl groups 
of SP-A, as well as Van-der-Waals bonds, may also contribute to SP-A binding. 
The two materials with the highest SP-A adsorption bear surface modifications that 
also feature aliphatic residues (PMO- and PL-mNPs). Cederval et al. showed that 
hydrophobic particles bound higher amounts of plasma proteins compared to less 
hydrophobic materials [114, 115], implying that the potential to undergo hydrophobic 
interactions is strongly related to protein adsorption. Concerning SP-A, mNPs could 
form rather non-specific hydrophobic interactions with hydrophobic clusters at the 
surface of the SP-A macromolecular complex, including certain regions in the collagen 
stem. The fact that PMO-mNPs also show the highest adsorption of BSA when 
compared to other tested mNPs, confirms that such hydrophobic interactions may 
rather lead to a non-specific binding in terms of identity of the adsorbed protein 
(Figure 7.6). 
In terms of its biological activity, SP-A can be described as a broad spectrum 
pulmonary opsonin, whose primary function is to bind foreign materials after 
inhalation and contact with the ALF [43], and moreover has a distinct preference to 
bind hydrophobic structures [44]. Besides, due to the collectin character of SP-A, there 
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is also the possibility that binding of this molecule is mediated by some specific 
interactions with chemical patterns and moieties on the particle surface. It has been 
reported that SP-A is also able to specifically bind lipid ligands such as lipid A or 
dipalmitoyl-phosphatidylcholine (DPPC). Indeed, SP-A features a lipid binding site, and 
is overall preferred to interact with lipophilic ligands [44]. Thus, the significantly 
higher binding of PMO- and PL-mNPs might also be partly explained with this general 
preference of SP-A for lipophilic patterns.  Furthermore, the fact that PL-mNPs 
demonstrated high SP-A binding could be linked to the naturally high phospholipid-
association of SP-A in PS [35, 116]. 
In contrast to SP-A, BSA plays an important role in the regulation of the osmotic 
pressure in the blood, and has not necessarily the function to bind to foreign material 
with high affinity. This is well in line with the generally observed lower binding of BSA 
compared to SP-A for all nanomaterials studied (Figure 7.6). 
Concerning possible biological responses as a consequence of SP-A adsorption to 
deposited nanoparticles in the deep lungs, a major question of interest is certainly 
their interactions with AMs [110]. Earlier studies revealed that SP-A bound to 5 nm 
gold particles caused a specific uptake by rat AMs, probably via coated pits [100]. 
Stringer et al. observed a fairly increased macrophage association of micron-sized 
titanium dioxide when pre-treated with isolated SP-A [59]. Unfortunately, these 
studies lacked a detailed particle characterization, and also did not really show that 
SP-A actually was adsorbed to the particles. Therefore, the role of SP-A in this process 
still remained to be evaluated. 
Our data clearly show that SP-A led to a significantly increase of mNP interaction with 
AMs when compared to BSA (Figure 7.7), in good correlation with the protein 
adsorption data for these mNPs (Figure 7.6). Such effects, however, were not observed 
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for BSA. Overall, these results underline that the priming of mNPs with two different 
proteins, both relevant for different compartments, can cause significant differences in 
the interaction with cells, here with AMs. We may speculate that SP-A here forms a 
more effective corona with greater potential to trigger the mNPs interaction with AMs. 
BSA, however, does also adsorb to some extent to the mNPs, but seems to shield free 
surface groups of the mNPs, and prevents them hereby from binding to cellular 
membranes. 
Besides the specific effects exerted by adsorbed proteins, one has to consider the 
influence of protein binding on other particle characteristics such as size or surface 
charge, and the involved consequence for the interplay with cells. Here, our results 
reveal both changes in zeta-potential (Table 7.2) upon protein adsorption, and also the 
formation of particle agglomerates for some mNPs, namely CH- and PMO-mNPs 
(Figure 7.8). Such an increase in particle size is likely to effect the mNP sedimentation 
onto the cells, thereby enhancing cell interactions [117]. Additionally, it is known that 
a size of 1-5 µm increases binding and uptake by AMs, compared to nanoparticles, 
which have been reported to be internalized rather sporadic and non-specific [63]. In 
this context, for some of the mNPs SP-A probably also fulfills its physiological function 
as a broad spectrum opsonin by aggregating foreign materials for an enhanced 
clearance [38]. These findings emphasize the importance to account for particle size 
and size distribution [117], and that especially in case of CH- and PMO-mNPs both 
particle size and SP-A might contribute to the high AM interaction. 
However, the strongly SP-A binding PL-mNPs appeared to still remain dispersed as 
nanoparticles, regardless of the presence or absence of any protein studied (Figure 
7.8). Especially for these nanoparticles, it is therefore very likely that the observed 
biological effects are mediated by adsorbed SP-A, as the cell association here was 
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significantly higher than for either mNP only or when pre-incubated with BSA (Figure 
7.7). Furthermore, SP-A significantly increased the uptake of PL-mNPs compared to 
protein-free medium (Figure 7.10J). 
These results lead us to the conclusion that nanoparticles with high binding to SP-A, 
while retaining their colloidal stability, might bear great potential to interact more 
specifically with AMs, favoring their internalization and clearance. It might her be 
speculated that a possible the reason for such behavior could be an oriented 
adsorption of SP-A via its CRD. In case of such a binding mode, the collagenous part of 
the protein, which is known to facilitate macrophage interaction via receptor binding 
[118], would be not involved in the nanoparticle binding of the protein, and therefore 
still available to enable a receptor-mediated particle internalization. 
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7.6.  Conclusion 
Overall, our findings suggest, that SP-A - when binding to mNPs - can favor their cell 
adherence and especially their uptake by AMs. As a matter of fact, adsorption of SP-A 
to nanoparticles may significantly enhance this otherwise rather sporadic and non-
specific process [63]. The formation of a SP-A – corona could also be determinant to 
even define the interplay of the particles with other cells such as Alveolar type 1 (AT 1) 
- or AT2 - cells or dendritic cells, DC) of the alveolar mucosa [110]. However, a 
potential participation of other PS components such as other surfactant proteins and 
lipids cannot be discarded and should be further investigated, as for other inhalable 
substances such as pollen grains, a SP-D – mediated increase in DC uptake could 
recently be shown by Winkler et al. [119]. 
In summary, this study first and foremost describes both the adsorption of SP-A to 
nanomedically relevant nanoparticles, and a subsequent biological effect, exemplified 
by macrophage uptake. However, more detailed studies focusing on the molecular 
determinants defining SP-A – nanoparticle interactions, as well as elucidation of SP-A 
– mediated uptake mechanisms by AMs are necessary. The fact that lung relevant SP-A 
causes a significant different AM response to nanoparticles in comparison to albumin 
emphasizes, that the protein corona formed around a nanoparticle varies with the 
respective physiological compartment in the body, and as a consequence the corona-
mediated biological effects. 
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8.1.  Abstract 
In this study, we compared the effect of surfactant-associated protein A (SP-A) and D 
(SP-D) regarding the clearance of magnetite nanoparticles (mNP) with either more 
hydrophilic (starch) or hydrophobic (phosphatidylcholine) surface modification by an 
alveolar macrophage (AM) cell line (MH-S) using flow cytometry and confocal laser 
scanning microscopy (CLSM). Both proteins stimulated AM interaction compared to 
pristine nanoparticles, whereas each protein appeared to preferentially trigger the 
uptake of one respective tested nanoparticle modification. Using gel electrophoretic 
and dynamic light scattering (DLS) methods, we were able to demonstrate that 
observed cellular effects were related to protein adsorption but also protein-mediated 
interference with colloidal stability. We further investigated the influence of 
surfactant lipids as major surfactant component on nanoparticle uptake by AMs. 
Synthetic surfactant lipid as well as isolated native surfactant (NS) preparations 
significantly modulated the effects exerted SP-A or SP-D, resulting in comparable 
levels of macrophage interaction for both types of nanoparticles, regardless of their 
surface modification. Our findings suggest that in the presence of both surfactant 
lipids and proteins the clearance by AMs might essentially be equal even for 
nanoparticles with considerably different properties. 
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8.2.  Introduction 
With respect to potential exploitation of nano-sized particulate systems for 
pharmaceutical or medical purposes, inhalation and pulmonary deposition of 
nanoparticles is a vividly discussed topic among researchers from Nanomedicine. 
However, potential adverse health effects from nanoparticles are likewise a scope for 
Nanotoxicologists, and risk assessment of such systems in whatever application is a 
topic of increasing concern to regulatory agencies as well as to the public. 
Ongoing controversial discussions on use of nanotechnology emphasize even more the 
demand to carefully elucidate the biological fate of inhaled nanoparticles in the human 
body [19, 120], in particular their clearance, which can either be exerted by the 
mucociliary escalator, by AMs, or by translocation across the epithelial layer [4, 67]. 
With respect to nanoparticle inhalation to respiratory tract, there is an urgent request 
to fundamentally understand the bio-nano interactions such systems undergo after 
deposition [10, 55]. This is a key issue and challenge for scientist both working in the 
field of Nanomedicine as well as Nanosafety. 
Especially non-cellular elements of the so-called air-blood barrier may play a key role 
here, as this is the first biological matter nanoparticles get in contact with after 
inhalation and deposition in the lungs. In the peripheral deep lungs, the so-called 
alveolar lining fluid (ALF), an ultra-thin layer that consists of an aqueous subphase and 
a surface-active lipid-protein mixture, known as pulmonary surfactant (PS), covers the 
epithelial cells. In the conducting airways, it is mucus - a rather thick layer with gel-sol 
characteristics – that forms the main hurdle to overcome for deposited particles, when 
the underlying epithelium is the target [60, 111]. However, PS is continuous and 
spreads form the distal to the proximal lungs, whereas it consequently is positioned at 
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the air-interface making it the most outer part of the air-blood barrier [5, 34]. In many 
cases the deep lungs are the desired deposition-site in the respiratory tract for 
particle-based therapeutic systems. Hence, it is of outmost importance to take the 
non-cellular barriers into account when evaluating such formulations for inhalation 
purposes. 
Interactions between inhaled nanoparticles and the PS system are of increasing 
interest and were subject of several studies in the last years. However, recent work 
mainly focused on the influence such particles exhibit on the biophysical function of 
PS [47, 48, 50]. Such investigations are of great importance from a Nanosafety 
perspective, as they intend to find out if and how inhaled nanoparticles can alter the 
respiratory function. Astonishingly, however, there is still only little known on role of 
surfactant biomolecules regarding their binding to nanoparticles as well as their 
potential to influence subsequent biological effects, such interaction with AMs, 
representing the main clearance mechanism for particles from the peripheral lungs 
[55, 56, 63]. 
PS consists of about 90% lipids and 10% proteins [34]. Among the proteins there are 
four surfactant proteins (SP-A, -B, -C, and –D), which exert various functions within PS. 
Whereas SP-B and SP-C are rather small peptides that interact with surfactant lipids 
and thereby contribute to proper biophysical surfactant functionality [37], especially 
the pulmonary collectins SP-A (630 kD) and SP-D (520 kD) are of exceeding interest 
regarding bio-nano interactions, as they fulfill important immunological functions by 
acting as versatile opsonins [38]. Their position close to the air-liquid of the alveoli 
ideally enables these two proteins to interact with and bind to airborne particulate 
matter deposited into the deep lungs and getting in contact with PS [44]. Furthermore, 
the fact that SP-A and SP-D can influence the activity of AMs regarding uptake of 
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particulate matter possibly also allocates them a key role in clearance of inhaled 
nanoparticles [43].  
In chapter 7 it was shown that nanoparticle uptake by AMs can be triggered by SP-A, 
pointing to the importance of surfactant proteins as relevant biomolecules 
determining the fate of inhaled nanoparticles in the deep lungs [121]. 
SP-D, however, is most probably of an evenly great importance in terms of protein-
nanoparticle interactions, as there is evidence that this protein can influence the 
phagocytosis of non-living particulate matter [122].  
Hence, we here studied and compared the potential of SP-A and SP-D regarding their 
effects on nanoparticle uptake by AMs using MH-S cells, an immortalized murine AM 
cell line. Further, we analyzed the binding of SP-A and SP-D to nanoparticles and their 
impact on colloidal stability. However, surfactant lipids, accounting for the major part 
of PS, might modulate the action of surfactant proteins, and therefore were also 
investigated. 
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8.3.  Materials and Methods 
8.3.1. Materials 
Magnetic nanoparticles (mNPs; nano-screenMAG, Magnetite core with Starch- (ST-
mNP) or Phosphatidylcholine- (PL-mNP) matrix) were purchased from chemicell 
GmbH (Berlin, Germany). The nanoparticles were ordered with a yellow-green 
fluorescence color (Ex: 476 nm, Em: 490 and 515 nm) and a hydrodynamic diameter of 
150 nm as indicated by the manufacturer. Human SP-A from alveolar proteinosis 
patients was isolated and characterized as described in section 5.2.2. Protein 
concentration was determined using a bicinchoninic acid assay kit according to the 
manufacturers instructions (Sigma, Munich, Germany). Recombinant human SP-D was 
obtained from R&D systems (Minneapolis, MN, USA). The lyophilized protein was 
reconstituted at 100 µg/ml in PBS (Dulbecco’s Phosphate Buffered Saline; Sigma) prior 
use or stored as aliquots at -20°C. Synthetic 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC; PC 16:0/16:0) and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-rac-glycerol (POPG; PG 16:0/18:1) were received from Lipoid GmbH 
(Ludwigshafen, Germany). Palmitic acid (PA) was purchased from Sigma. NS was 
isolated from porcine lungs obtained from a local slaughterhouse as described in 
section 5.2.1. Cell culture reagents were obtained from Gibco (Invitrogen, Carlsbad, CA, 
USA), if no other source is stated. All other chemicals and reagents were purchased 
from Sigma unless indicated otherwise. 
8.3.2. Scanning Probe Microscopy (SPM) and Scanning Electron Microscopy (SEM) 
For SPM measurements, samples were prepared by coating freshly cleaved mica with 
aqueous suspensions of mNPs. Therefore, a 1:100 dilution of the stock solution (25 mg 
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solid content per ml as provided by the manufacturer was prepared, followed by 
gentle drying with compressed air. SPM scans were performed using a Multimode V 
(Veeco, USA). Samples were scanned in non-contact mode with scan rates below 1Hz 
using standard non-contact mode cantilevers (OMCL-AC160TS, Olympus, Essex, Great 
Britain) as described elsewhere [111]. For SEM imaging, samples were prepared by 
deposition of mNP suspensions (approximately 250 µg/ml in MQ-water) on cleaned 
silicon wafers. Wafers were subsequently dried under air stream and gold coated 
(Auto Fine Coater JSC 1300, Jeol, Akishima, Japan). Nanoparticles on sputtered wafers 
were imaged with a JSM 7001F Field Emission SEM (Jeol, Akishima, Japan) under high 
vacuum conditions and room temperature. Accelerating voltage was 20 kV with a focal 
distance of 10 mm. 
8.3.3. Cell Culture 
Murine AMs (MH-S; ATCC CRL-2019, Wesel, Germany) were cultured under adherent 
conditions in cell culture medium (RPMI 1640 with L-glutamine supplemented with 
10% (v/v) foetal calf serum (FCS; PAN Biotech, Aidenbach, Germany), 1% (v/v) HEPES, 
25mM D-glucose, 18 mM sodium bicarbonate (Merck), 1 mM sodium pyruvate and 
0.05 mM β-mercaptoethanol). For uptake experiments, 2x105 cells per ml were 
seeded in 24-well plates (for flow-cytometry studies; Greiner Bio-One, Frickenhausen, 
Germany) or in 24-well imaging plates (for CLSM studies; zell-kontakt®, Nörten-
Hardenberg, Germany) and cultivated for 48 h in cell culture medium. Cells were 
incubated at 37°C under humidified 5% CO2 atmosphere. 
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8.3.4. Flow Cytometry - Based Cell Association Assay 
Test formulations were prepared as follows: 10 µl ST- or PL-mNP of a 550 µg/ml stock 
suspension in RPMI were added to 190 µl RPMI supplemented with surfactant proteins 
(SP-A or SP-D at 0.5, 1, 5, 10 or 20 µg/ml), surfactant lipids (0, 1, 10, 25, 50 or 100 
µg/ml total lipids) or NS (100 µg/ml total protein). Prior each uptake experiments, cells 
were washed with RPMI (w/o FCS) to remove serum proteins and equilibrated for 30 
min at 37°C.  After this pre-incubation, RPMI was replaced by nanoparticle test 
formulation (1.532 x 1010 mNPs per ml) and incubated under gentle shaking (150 rpm; 
IKA MTS 2/4 digital, IKA, Staufen, Germany) at 37° C for 90 min. All experiments were 
performed in the absence of FCS to differentiate effects mediated by the particular 
surfactant proteins. After nanoparticle exposition, cells were washed twice with PBS 
and harvested for flow cytometric analysis using a FACSCalibur (Becton Dickinson, 
Franklin Lakes, NJ, USA). Five to ten thousand events were acquired in a gate based on 
forward and side scatter. Level of mNP-macrophage interaction measured as increase 
of fluorescence in the Fl-1 – channel and are subsequently referred to as per cent 
positive cells. Percent values of events with Fl-1 above 101 of cells only were 
subtracted from each sample as background. Data analysis was carried out with 
FlowJow (Version 8.8.6; Tree Star Inc., Ashland, OR, USA). Experiments were 
performed in duplicates and repeated at least three times. 
8.3.5. CLSM - Based Uptake Study 
Visualization experiments were carried out in analogy to flow cytometry-based assays 
(see above). After 90 min incubation at 37°C under gentle shaking, cells were washed 
twice with PBS. Cell membranes were subsequently stained with Rhodamine riccinus 
communis agglutinin I (RRCA; 1:400 in PBS; Vector Laboratories, Burlingame, CA, USA) 
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at 37°C for 10 min and cells were fixed with formaldehyde (4% (v/v) in PBS) for 10 min 
after two intermediate PBS washing steps. A Zeiss LSM 510 with META detector (Carl 
Zeiss AG, Oberkochen, Germany), equipped with a 40x water immersion objective was 
used to visualize the specimens. Micrographs with more than 10 cells recorded in the 
equatorial plane of the cells were used for a quantitative discrimination between 
internalized and adherent nanoparticles. Cells were visually counted for each 
micrograph (n = 7 micrographs per condition), and cells with at least one nanoparticle 
located inside the membrane boundary were expressed as per cent uptake-positive 
cells of total cell number. Images were analyzed using Volocity LE (Version 5.3.1; 
Perkin Elmer, Waltham, MA, USA). Experiments were performed in duplicates and 
repeated two times. 
8.3.6. Protein Adsorption Study 
To investigate the adsorption of SP-A and SP-D to nanoparticles, 20 µl ST-mNP or PL-
mNP as suspensions of 2 mg/ml in RPMI (RPMI 1640 with L-glutamine, supplemented 
with 1% (v/v) HEPES, 25 mM D-glucose, 18 mM sodium bicarbonate (Merck), 1 mM 
sodium pyruvate) were incubated with 180 µl protein solution (10 µg/ml in RPMI) for 
10 min at 37°C. After incubation, nanoparticle-protein complexes were removed from 
supernatants using magnetic separation (Magna GrIP™ Rack, Millipore Coporation, 
Billerica, MA, USA). Nanoparticle pellets were resuspended with 200 µl RPMI and again 
separated magnetically. After removal of wash-supernatants pellets were resuspended 
in 40 µl SDS-PAGE sample buffer (25% (w/v) Glycerol, 60 mM Tris-HCl pH 6.8, 2% (w/v) 
SDS (Serva, Heidelberg, Germany), 0.1% (w/v) Bromophenol Blue (Merck, Darmstadt, 
Germany), 5% (v/v) β-mercaptoethanol in MQ-water) and heated in a waterbath at 
95°C for 5 min to elute adsorbed proteins from the particles. Protein samples were 
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separated on 10% SDS-polyacrylamide gels at 130 V for 1 h using a MiniProtean 
Tetracell (BioRad, Munich, Germany). Gels were subsequently stained with colloidal 
Coomassie (PageBlue, Fermentas, St.Leon-Rot, Germany). Gel analysis and protein 
quantification using SP-A or SP-D standards (1000 ng band) was carried out with 
Image Lab (Version 4.0 build 16; BioRad, Munich, Germany). Experiments were 
repeated three times. 
8.3.7. Nanoparticle Size and Zeta-Potential 
All tested nanoparticles were characterized in terms of hydrodynamic diameter and 
size distribution by means of DLS. Briefly, 10 µl mNP (550 µg/ml in RPMI) were mixed 
with 200 µl MQ-water or test medium (RPMI), supplemented with 1, 5, 10 or 20 µg/ml 
SP-A or SP-D, respectively, or 100 µg/ml surfactant lipids. Then, samples were diluted 
by addition of 800 µl RPMI and subsequently measured using a Zetasizer Nano-ZS 
(Malvern Instruments, Malvern, UK). Zeta-potentials were determined using the same 
apparatus. Experiments were at least repeated twice.  
8.3.8. Rose Bengal Assay 
Surface hydrophobicity of tested nanoparticles was assessed using the Rose Bengal 
(RB) assay as described by Müller et al. [23]. Briefly, 150 µl of mNP suspension (5 
mg/ml to 78.125 µg/ml (1:1 dilutions) in PBS, pH 7.4) were incubated with 150 µl RB 
(40µg/ml in PBS) for 30 min at RT. As control, 150 µl RB (40µg/ml, Sigma) were 
incubated with 150 µl PBS only. After incubation, samples were centrifuged at 10,835 
x g for 20 minutes at 4°C. Supernatants were carefully removed and absorption at 542 
nm was measured using an Infinite 200 M multimode microplate reader (Tecan Group 
Ltd., Männedorf, Switzerland). RB concentration in supernatants (free amount in 
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dispersion medium) was determined using a RB calibration curve (40 – 0.625 µg/ml). 
The nanoparticle-adsorbed amount of RB was calculated according to equation 1: 
[Adsorbed amount] = [Control] – [Free amount in dispersion medium]  (1) 
Subsequently, the partitioning coefficient PQ of RB between the nanoparticle surface 
and the dispersion medium was calculated for each nanoparticle concentration using 
equation 2: 
PQ = [Adsorbed] / [Free amount in dispersion medium]    (2) 
PQ was plotted against the total nanoparticle surface (µm2), assuming spherical 
particles with diameters as determined by DLS. The slope of the resulting line was 
used as a measure for relative hydrophobicity. 
8.3.9. Preparation of Surfactant Lipid Vesicles 
Surfactant lipids (DPPC, POPG, PA) were dissolved in chloroform/methanol (3:1, v/v) to 
prepare stock solutions of concentration of 20 mg/ml (w/v) each. Amounts of 
surfactant lipid stock solutions were mixed to obtain a final weight ratio of 28:9:5.6 
(DPPC/POPG/PA) with a total lipid mass of 1 mg, and organic solvents were evaporated 
under nitrogen with subsequent centrifugation under reduced pressure for 1 h using a 
Concentrator plus (Eppendorf, Hamburg, Germany). Subsequently, the dried lipid 
mixture was rehydrated with 1 ml RPMI on a Thermomixer (Eppendorf, Hamburg, 
Germany) at 800 rpm and 48 °C for 1 h. The resulting multilamellar suspensions were 
sonicated for 3 min (bursts of 0.6 s, 0.4 s between bursts) using a 2 mm microtip with 
a Branson Digital Sonifier 250 (Branson Ultrasonics, Danbury, CT, USA) at 10% 
amplitude, to produce unilamellar vesicles. Surfactant lipid vesicles were 
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characterized in terms of size distribution, resulting in a mean peak size of 50.7 nm as 
determined by DLS. 
8.3.10. Statistics 
Differences in protein adsorption were analyzed using the Student’s t-test. Differences 
in nanoparticle-macrophage interaction studies were analyzed by One-way ANOVA 
followed by Newman-Keuls posthoc tests using Graphpad 5 for Mac. For all tests p < 
0.05 was considered as significant difference. 
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8.4.  Results 
8.4.1. Comparison of SP-A and SP-D 
In order to study the effect of SP-A and SP-D on nanoparticle association with and 
uptake by macrophages, we choose mNPs as a model system. These particles were 
composed of the same magnetic core material but decorated with different coatings, 
resulting in different surface properties while showing comparable diameters with 
similar morphology (Table 8.1 and Figure 8.1). 
 
Table 8.1. Characteristics and Properties of Used mNPs. 
 
* Surface modification as indicated by the manufacturer (chemicell GmbH, Berlin, Germany). 
 
‡ Hydrodynamic diameter and poly-dispersity index (PdI) as determined by DLS using a Zetasizer Nano-ZS 
(Malvern Instruments). Data is shown as mean ± SD (n=3). 
† Zeta-potential values were measured using the same machine and are displayed as mean ± SD (n=3). 
 
 
Name 
Surface-
material 
In MQ- 
water 
 
In RPMI 
 In MQ-
water 
In RPMI 
  
Size 
(nm) ‡ 
PdI ‡ 
 
Size 
(nm) ‡ 
PdI ‡ 
 Zeta-
potential 
(mV) † 
Zeta-
potential 
(mV) † 
ST-mNP Starch 
148.2 ± 
1.6 
0.180 ± 
0.023 
 145.3 ± 
3.0 
0.154 ± 
0.012 
 - 4.15 ± 0.22 -3.02 ± 0.4 
PL-mNP 
Phosphatidyl
-choline 
126.4 ± 
1.5 
0.064 ± 
0.013 
 121.4 ± 
0.9 
0.047 ± 
0.023 
 - 34.5 ± 0.23 -25.2 ± 1.7 
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Figure 8.1. Microscopic images of used mNPs. 
SPM- (left) and SEM-images (right) of starch- (ST) and phosphatidylcholine- modified mNPs reveal a 
comparable cluster like appearance with diameters between 100 and 200 nm. Scale bars in SEM 
micrographs indicate a distance of 100 nm. 
 
 
We found that SP-D mainly triggered the cellular association of ST-mNP (Figure 8.2A), 
whereas SP-A predominantly increased the interaction of PL-mNPs with cells (Figure 
8.2B). SP-A was able to significantly affect the cell association already at 
concentrations of 5 µg/ml, while this effect reached a plateau at higher tested 
concentrations. 
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Figure 8.2. Association of Nanoparticles with AMs as a Function of the Presence of 
Increasing Concentrations of SP-A or SP-D as Determined by Flow Cytometry. 
(A) Starch-modified mNP or (B) Phosphatidylcholine-modified mNPs (1.532 x 1010/ml) were exposed to 
AMs in the absence or presence of increasing surfactant protein concentrations and incubated for 90 min. 
Cells with Fl-1 > 101 were considered as positive cells for nanoparticle association and uptake (expressed 
as percent of positive cells with respect to total cells) compared to control (cells only). Data shown as 
mean ± SD (n≥3). Asterisk indicates a significant difference with p < 0.05, compared to mNP in the absence 
of proteins. 
 
In contrast, SP-D – mediated effects were rather moderate, reaching statistical 
significance only at a four-fold higher protein concentration. However, no saturation 
in cell binding of these nanoparticles could be seen under tested concentrations. 
Bearing in mind that the physiological concentration of SP-D in the ALF in non-smoker 
humans is approximately 1.3 µg/ml [123], concentrations above 20 µg/ml would be far 
beyond physiological relevance and were therefore not tested in this study. 
Next, we used CLSM to discriminate between cellular adherence and internalization of 
nanoparticles (Figure 8.3). Here, we focused on the effects of SP-D on ST-mNPs and SP-
A on PL-mNPs, respectively, corresponding to the previously observed increased 
cellular responses. 
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Figure 8.3. Uptake of Nanoparticles by AMs in the Presence and Absence of SP-A or SP-D 
as Studied by CLSM. 
Representative micrographs are shown for Starch-modified mNP (A,C) or Phosphatidylcholine-modified 
mNPs (B,D) (1.532 x 1010/ml, in green) after 90 min exposition to AMs (MH-S cells; membrane in red) in 
absence (mNP only in buffer (A,B) or presence of (C) SP-D (10 µg/ml) or (D) SP-A (10 µg/ml). Scale bar 
indicates a distance of 20 µm. (E) Particle uptake determined by visual counting of cells with at least one 
nanoparticle internalized related to total cell count (% positive cells). Data shown as mean ± SD (n=14 
images). Asterisk indicates a significant difference with p < 0.05. 
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Micrographs recorded at the cellular equatorial plane reflected the trend from flow 
cytometry measurements of an increased particle number per cell due to presence of 
surfactant proteins (Figure 8.3A-D). Image analysis for quantification cellular uptake 
revealed that this trend was also paralleled by an increase in nanoparticle 
internalization (Figure 8.3E), underscoring the role of surfactant proteins for uptake by 
AMs. Both SP-A and SP-D probably lead to an alteration of the nanoparticle’s outer 
appearance, apparently influencing the subsequent nanoparticle – cell interactions. 
Therefore, binding of surfactant proteins, as well as their impact on colloidal stability 
was investigated. 
8.4.2. Protein binding and colloidal stability 
Adsorption experiments revealed a pronounced binding of SP-A to PL-mNPs, whereas 
ST-mNPs only showed a low binding to this protein. This could be seen when samples 
were analyzed on Coomassie-stained SDS-PAGE gels (Figure 8.4A), where the SP-A 
band corresponding to particle-bound protein was more intensive for PL-mNPs 
compared to ST-mNPs, which was confirmed by densitometry measurements of the 
protein signals (Figure 8.4B). 
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Figure 8.4. Adsorption of SP-A and SP-D to Nanoparticles as Affected by Particle Coating 
and Hydrophobicity. 
(A) Representative SDS-PAGE gel displaying the adsorbed surfactant proteins (SP-A in the left lanes or SP-
D in the right lanes) eluted from Starch- (ST) or Phosphatidylcholine-modified (PL) mNP; MWStd stands 
for molecular weight standard. (B) Adsorbed amount of protein in nanogram of protein per band. (C) Plot 
of RB - partitioning coefficient (PQ) as a function of total nanoparticle surface area (µm2). The slope of the 
lines was considered as a measure of relative nanoparticle hydrophobicity. Data shown as mean ± SD 
(n=3). Significant differences between the two proteins are indicated with asterisks (p < 0.05). 
 
However, when binding of SP-D was studied, we observed an opposite trend, as this 
protein had a higher affinity to ST-mNPs than to PL-mNPs (Figure 8.4B). As 
hydrophobic interactions are described as a main contributor for protein-nanoparticle 
interactions [19], we performed a RB assay to characterize the used nanoparticles in 
terms of surface hydrophobicity [23]. The slopes deduced from plotting the 
partitioning coefficient of the hydrophobic dye RB as a function of total nanoparticle 
surface area can be considered as a relative measure for hydrophobicity (Figure 8.4C). 
PL-mNPs revealed to have a 10-fold steeper slope than ST-mNPs, meaning that here 
higher amounts of RB were bound by the same total surface area compared to ST-mNP, 
indicating an overall more hydrophobic character for PL-mNPs. 
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Besides protein adsorption, we further studied the colloidal stability of the two tested 
nanoparticle types after incubation with SP-A or SP-D, respectively, at concentrations 
corresponding to the previous macrophage experiments, using DLS (Figure 8.5). 
 
 
Figure 8.5. Influence of SP-A or SP-D on Colloidal Stability of Nanoparticles.  
Increasing concentration of SP-A or SP-D were added to Starch-modified mNPs (ST-mNP; left) or 
Phosphatidylcholine-modified mNPs (PL-mNP; right). Hydrodynamic diameter (Z-average, size in nm) 
was determined subsequently after mixing using DLS. Data shown as mean ± SD (n=6). 
 
Hydrodynamic diameter of ST-mNPs was not affected by SP-A and only slightly 
increased when measured after incubation with SP-D (171.6 ± 6.7 nm at 20 µg/ml) 
compared to absence of protein (167.1 ± 4.5 nm). In case of PL-mNPs, however, 
measurements revealed the formation of agglomerates in presence of SP-A at a 
concentration of 10 µg/ml or higher, whereas SP-D did not cause such an effect. 
Overall, we disclosed that the interplay of AMs with mNPs can be influenced by either 
SP-A or SP-D, due to their particle adsorption as well as their impact on particle 
stability. These findings point to their relevance for bio-nano interactions in the ALF. 
PS, however, is a complex mixture composed of both lipids and proteins [34]. Hence, 
inhaled nanoparticles – in contrast to such applied intravenously - will never come 
Chapter 8: Influence of Surfactant Components on Uptake 
 93 
into contact with proteins only. In fact, as soon as nanoparticles get in contact with the 
PS system they will also interact with surfactant lipids. 
8.4.3. Effect of Surfactant Lipids 
To address this issue, we prepared small unilamellar vesicles composed of 
dipalmitoyl-glycerophosphocholine, palmitoyl-oleoyl-glycerophosphoglycerol and 
palmitic Acid (DPPC/POPG/PA), resulting in membrane structures that are known to 
have PS-like properties [124]. Then, we subsequently studied nanoparticle uptake by 
AMs in the presence of increasing DPPC/POPG/PA vesicle concentrations to explore 
effects of surfactant lipids in a well-defined system (Figure 8.6). 
 
 
Figure 8.6. Effect of Surfactant Lipids on the Association of Nanoparticles with AMs. 
(A) Starch- (ST) or Phosphatidylcholine-modified (PL) mNP (1.532 x 1010/ml) were incubated with AMs 
(MH-S cells) for 90 min in the absence or presence of 25, 50 or 100 µg/ml (total lipids) of surfactant-like 
membrane vesicles composed of DPPC, POPG and PA. Cells with Fl-1 > 101 were considered as positive 
cells for nanoparticle association and uptake (plotted as percent of positive cells with respect to total 
cells) compared to control (cells only). Data shown as mean ± SD (n=6). Images are representative 
micrographs of AMs (membrane in red) with ST-mNPs (B) or PL-mNPs (C) (in green), both in the presence 
of 100 µg/ml DPPC/POPG/PA. Scale bar indicates a distance of 20 µm. 
 
At first, PL-mNPs showed a much higher cell interaction than ST-mNPs when studied 
in buffer only (0 µg/ml DPPC/POPG/PA), and also interacted to a comparable extent at 
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any DPPC/POPG/PA concentration tested (Figure 8.6A). ST-mNPs, however, revealed a 
more pronounced cell binding with increasing DPPC/POPG/PA concentrations, 
reaching a similar level of cell interaction as PL-mNPs at 100 µg/ml. This trend was 
also confirmed by CLSM (Figure 8.6B and C). 
Nonetheless, in the in vivo situation, surfactant lipids are highly associated with 
surfactant proteins. Consequently, we also tested DPPC/POPG/PA vesicles 
supplemented with either SP-A or SP-D resulting in physiological lipid-protein ratios 
(Figure 8.7). 
 
 
Figure 8.7. Modulating Effect of Surfactant Lipids on the Effect of SP-A and SP-D to 
Promote Association of mNPs with AMs. 
(A) Starch- (ST) or Phosphatidylcholine-modified (PL) mNP (1.532 x 1010/ml) were incubated with AMs 
(MH-S cells) for 90 min in the absence (mNP only in buffer) or presence of DPPC/POPG/PA vesicles (100 
µg/ml) with and without 5 µg/ml SP-A or SP-D, respectively. Cells with Fl-1 > 101 were considered as 
positive cells for nanoparticle association and uptake (% positive cells). Data shown as mean ± SD (n=6). 
Asterisk indicates a significant difference with p < 0.05. 
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Surprisingly, neither SP-A nor SP-D did influence the association of mNPs with cells 
when studied in combination with DPPC/POPG/PA, showing actually similar levels of 
macrophage binding as in the absence of the proteins (Figure 8.7A, “mNP only”). For 
ST-mNPs, cellular interaction in presence of DPPC/POPG/PA showed a general increase, 
compared to conditions tested without these lipids (Figure 8.7A), as observed in the 
experiments above. In case of PL-mNPs, however, stimulation of SP-D was increased, 
whereas stimulation of SP-A was decreased, resulting in similar levels for all three 
conditions in the presence of DPPC/POPG/PA (Figure 8.7B). In fact, it seemed that 
presence of surfactant lipids particularly neutralized the effect observed with SP-A 
only (w/o), revealing a comparable trend with respect to cell binding as ST-mNPs 
when studied in the presence of both surfactant proteins and surfactant lipids. 
However, as size measurements of nanoparticles in presence of DPPC/POPG/PA 
confirmed, surfactant lipids (DPPC/POPG/PA) did not cause any formation of particle 
agglomerates (Figure 8.8). For SP-A and PL-mNPs, particle agglomeration was even 
prevented, suggesting that surfactant lipids obviously can account for maintenance of 
colloidal stability. 
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Figure 8.8. Influence of Surfactant Lipids on Colloidal Stability of Nanoparticles in the 
Presence and Absence of SP-A. 
Starch-modified mNPs (top) or Phosphatidylcholine-modified mNPs (bottom) were studied in absence 
(mNP only), or in presence of DPPC/POPG/PA (100 µg/ml total lipids), with or without SP-A (5 µg/ml). 
Hydrodynamic diameter (Z-average, in nm) was determined subsequently after mixing using DLS. Data 
shown as mean ± SD (n=3). 
 
Regarding the in vivo situation, we must admit of course that these findings were 
obtained upon exposure of mNPs to a mixture of lipids and surfactant proteins, which 
is still an artificial model for PS. Hence, we also studied macrophage uptake of 
nanoparticles also in presence of NS, containing physiological ratios of surfactant 
lipids, hydrophobic surfactant proteins and SP-A, and therefore being of higher 
physiological relevance. The complexity of NS designates this isolate often as a 
biological standard to evaluate exogenous surfactant preparations [35, 82]. However, 
due to the fact that NS lacks SP-D, we additionally tested NS formulations spiked with 
amounts of SP-D that were in physiological ratio to SP-A (~ 10:1 (w/w) SP-A to SP-D). 
For ST-mNPs, NS lead to a considerable increase of nanoparticle uptake (Figure 8.9). 
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Figure 8.9. Association of Nanoparticles with AMs in Dependence on NS. 
Starch- (ST) or Phosphatidylcholine-modified (PL) mNP (1.532 x 1010/ml) were incubated with AMs (MH-S 
cells) for 90 min in absence (mNP only in buffer) or presence SP-A containing NS (100 µg/ml total protein) 
with and without 6 µg/ml SP-D (NS + SP-D). Per cent of cells with Fl-1 > 101 were considered as positive 
cells for nanoparticle association and uptake (% positive cells). Data shown as mean ± SD (n≥8). Asterisk 
indicates a significant difference with p < 0.05. 
 
Although percentage of positive cells was overall lower in comparison to 
DPPC/POG/PA (Figure 8.7A), the previously observed stimulating effect of surfactant 
lipids was here still confirmed. NS spiked with SP-D (NS+SP-D) further increased the 
association to significantly higher percentage of positive cells compared to mNPs in 
buffer only (mNP only). 
In case of PL-mNPs, however, cell binding was gradually equalized to that of ST-mNPs 
and rather low when investigated with either NS alone or NS supplemented with SP-D. 
Furthermore, uptake of PL-mNPs was significantly decreased in presence of NS, 
regardless if spiked with SP-D or not, when compared to mNP only. Astonishingly, 
both types of mNPs demonstrated a similar extent of macrophage interaction when 
studied in NS spiked with SP-D, being the most complex PS model used in this study. 
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8.5.  Discussion 
In the present study, we could demonstrate that the pulmonary collectins SP-A and 
SP-D both can significantly trigger the interaction of nanoparticles with AMs (Figure 
8.2 and 8.3). Additionally, we showed that observed cellular effects were preceded by 
protein adsorption, leading to an alteration of the nanoparticle surface properties, 
sometimes also causing particle agglomeration. With respect to the latter, the present 
study essentially confirmed the data we previously reported for SP-A [56, 121]. Such 
protein – mediated effects are thus the consequence of their adsorption to the 
nanoparticles, resulting in formation of a protein corona around the nanoparticles 
which determines their further biological fate [27, 125]. Here, we observed a 
pronounced binding of SP-A to PL-mNPs, whereas SP-D preferentially adsorbed to ST-
mNPs. These results foreground that surfactant protein binding is crucially dependent 
on the nanoparticle surface material, as both studied mNPs interacted differently with 
the respective proteins. 
Looking from a broader perspective, these findings might point to the distinct 
differences between these two surfactant proteins regarding their binding to 
biological structures [44]. Indeed, such variations in pattern recognition might also 
exist for the interaction with deposited nanoparticles. The tendency of the pulmonary 
collectins SP-A and SP-D to bind nanoparticles might be determined by the sum of 
general physicochemical interactions on the one hand, such as electrostatic or 
hydrophobic interactions, but also material-specific molecular interactions on the 
other hand. From electrostatic surface potential modeling it is known that SP-A is of a 
more hydrophobic nature than SP-D [126]. Thus, whereas SP-A might preferably bind 
lipophilic patterns, SP-D could have the tendency to interact with more polar 
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substrates [44]. This hypothesis is in consistence with our data from RB assay, as SP-A 
preferentially bound lipophilic PL-mNPs and SP-D tended to adsorb to the rather 
hydrophilic ST-mNPs (Figure 8.4B and C). Furthermore, SP-A is able to bind lipids such 
as lipopolysaccharide [44], but also DPPC [116], the major phospholipid in PS [34]. 
Additionally, SP-D was shown to bind pollen starch granules [122]. However, 
prospective studies will be necessary to further elucidate such interactions on a 
molecular level. 
Still, our data corroborate that adsorption of SP-A or SP-D to nanoparticles can occur 
and is largely governed by material and therefore surface properties of the 
nanomaterials. Moreover, we provide evidence that SP-A or SP-D – if considered 
individually – can have a striking impact on the fate of nanoparticles regarding 
macrophage clearance. 
Such triggering effects could possibly include protein-mediated agglomeration of the 
nanoparticles. SP-A for instance promotes aggregation of phospholipid vesicles, and is 
also known to self-aggregate under certain conditions [89, 116]. Hence, agglomeration 
of PL-mNPs as observed in this study might be partly explained taking these attributes 
into account (Figure 8.5). Further, SP-A-induced agglomeration could lead to both 
higher cell deposition and enhanced phagocytosis, the latter being generally described 
as a size-dependent process [63]. 
Besides that, one could also think of a receptor-mediated mechanism exerted by 
adsorbed surfactant proteins that facilitate endocytotic ingestion of a nanoparticle due 
to interaction with SP-A or SP-D binding receptors on the cellular surface of AMs, such 
as SPR210 or glycoprotein-340, respectively [38, 110]. Summarized, increased uptake 
by AMs most likely originates from both mechanisms occurring simultaneously and 
cooperatively, by which SP-A and SP-D probably act as a sort of “second messengers” 
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for nanoparticles, finally fulfilling their physiological function, which is binding to 
foreign material and promoting its clearance from the lungs. 
 
However, when particle clearance was studied in the presence of surfactant lipids, the 
effects exerted by surfactant proteins were significantly modulated, causing 
eventually even opposite effects.  
On the one hand, we found that uptake of ST-mNPs by AMs was increased in presence 
of surfactant lipids, regardless if studied with synthetic or naturally derived surfactant 
preparations (Figure 8.7A and 8.9). These data suggest that nanoparticles, when 
surrounded and coated with surfactant lipids can presumably be internalized by AMs 
to an elevated degree, providing a more rapid clearance. In this respect, PL-mNPs 
support such hypothesis, as these particles are already bearing a phosphatidylcholine-
coating and showed an overall enhanced interaction with AMs compared to ST-mNPs 
(Figure 8.6A, 0 µg/ml DPPC/POPG/PA). A similar influence of surfactant lipids was also 
reported in an earlier study by Stringer et al. when titanium dioxide microparticle 
uptake by AMs was studied in dependence on Survanta®, a complex surfactant lipid 
extract [59]. 
On the other hand, surfactant lipids seemed to counterbalance the effect of SP-A on 
the interaction of PL-mNPs with macrophages (Figure 8.7B and 8.9). These findings 
indicate that certain surfactant components appear here to have an inhibiting effect on 
AM activities. In fact, it is known that surfactant lipids can suppress stimulation of 
immune cells to maintain homeostasis in the host defense system at the air-interface 
[127], and such effects also seem to play an important role in macrophage clearance of 
larger particulate matter [53]. Therefore, a decrease in cellular interaction as observed 
towards PL-mNPs could be explained as an inhibiting effect of free surfactant lipids 
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preventing the AMs from overreaction. Such a behavior would also account for the 
prior finding where no further increase in cellular interaction was observed for PL-
mNPs in the presence of any DPPC/POPG/PA concentration studied (Figure 8.6A). In 
this context, it is also likely that free surfactant lipids act as competitive binding 
partners for SP-A, preventing the protein from sufficient nanoparticle binding and 
cross linking, and therefore enhanced particle agglomeration (Figure 8.8). Moreover, 
one could assume that in case of PL-mNPs, protein-nanoparticle complexes are already 
surrounded by layers of surfactant lipids, which then act as a sort of matrix impeding 
the above described second messenger effect of proteins. 
Taking the influence of surfactant lipids on nanoparticle uptake together, both 
stimulating and inhibiting effects can occur and probably interfere with each other. 
However, below the line, both types of nanoparticles interacted to an overall equal 
extent with AMs in the presence of NS, regardless of their different surface 
modifications. 
Besides that, surfactant lipid membranes composed of DPPC/POPG/PA as well as NS- 
preparations were also shown to modulate effects exerted by SP-A or SP-D only 
(Figure 8.7 and 8.9). These observations might also be related to the counterbalancing 
interplay of proteins and lipids in PS [127]. It could be well possible that different 
situations occur in different locations of the airways. The airspaces at the upper 
airways could be particularly enriched in collectins and other innate defense 
molecules, promoting capture of spurious particles by macrophages while in the 
alveolar spaces, rich in PS, the immuno-modulatory properties of phospholipids could 
dominate, preventing inflammation but deviating the nanoparticle fate towards a 
higher and longer persistence into the extracellular material. 
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Nevertheless, we could show that proteins can exert significant effects on the 
biological fate of nanoparticles (Figure 8.2). In this regard, our results support the 
protein corona theory according to which the dynamic layer of proteins formed 
around nanoparticles defines their biological identity [27]. So far, this theory has 
primarily considered interactions of nanoparticles with components of blood plasma. 
The major constituent of PS, however, is lipid. In fact, our data demonstrate that 
surfactant lipids can dramatically modulate protein-mediated effects (Figure 8.7 and 
8.9). Accordingly, surfactant lipids most probably influence the subsequent cellular 
effects within the ALF, assigning them as an important factor for pulmonary bio-nano 
interactions in the lungs. 
Apart from the question whether a corona is actually formed or not, it can be 
concluded that surfactant components can significantly interfere with nanoparticle 
clearance by AMs. Indeed, uptake of nanoparticles with different surface coatings and 
properties (e.g. different relative hydrophobicity) was shown to be essentially 
comparable under conditions close to the in vivo situation (i.e. in the presence of NS). 
One might speculate that surface association of surfactant proteins and lipids could 
result in a rather complex mixed corona around nanoparticles upon first contact with 
PS. As surfactant lipids are obviously highly relevant for bio-nano interactions in the 
lungs, we therefore would suggest an expansion of the protein corona theory by 
including lipids as another essential factor to influencing the pulmonary corona. Its 
detailed characterization would be an indispensable issue to be addressed in future 
investigations. 
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8.6.  Conclusion 
We believe that these findings are of general importance with respect to pulmonary 
drug delivery as well as inhalation toxicology. On the one hand, such assimilation 
might put hitherto existing targeting strategies using nanoparticles in question, as 
surface-ligands meant for cellular recognition could be masked by PS components and 
therefore inactivated to some extent. On the other hand, such behavior demonstrates 
that the outcome of the interplay between AMs and surfactant components is a highly 
effective biological barrier and clearance apparatus, not only for inhaled pathogens 
such as bacteria or viruses, but also for deposited nanoparticles, which might be 
beneficial for removal of unintentionally inhaled materials of this kind. 
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9.  Summary and Outlook 
 
“[...] It is the dynamical corona of associated biomolecules 
 that defines the biological identity of the nanoparticle.“ [27] 
 
This statement quoted from a review on protein-nanoparticle interactions by Lynch et 
al. gives an illustrative and concrete idea of what is meant by the term bio-nano 
interaction [27]. Interestingly, this quote was published in a review less than one year 
before the work presented in this thesis was initiated. This narrow time frame makes 
clear, that the whole concept of the corona theory and its implications for the 
biological behavior of nanoparticles in the body is a rather new topic in nano-science, 
which actually is still under discussion and not yet fully accepted among researchers 
in the field. Nevertheless, publications on this topic so far reveal that the concept of 
this theory has primarily been considered regarding interactions of nanoparticles with 
components of blood plasma, but has been mostly neglected to date with respect to 
inhaled nanoparticles. 
 
The aim of presented work was to explore bio-nano interactions relevant for the 
peripheral, i.e. alveolar region of the lungs as the main site of interaction for 
nanoparticles deposited in the respiratory tract. In this context, it could be 
demonstrated that surfactant proteins as primarily encountered pulmonary surfactant 
components are highly active molecules with pronounced potential to bind 
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nanoparticulate matter in a material-dependent manner (as exemplified in chapter 6 
and 7 using SP-A as the predominant surfactant protein). 
Additionally, it was shown that with respect to cellular interactions, nanoparticles 
behave significantly different under lung-relevant conditions. Namely, it was shown 
that due to their nanoparticle binding, pulmonary surfactant proteins have the 
potential to trigger subsequent cellular effects, as exemplified by alveolar macrophage 
(AM) uptake. This was shown for nanoparticle uptake in the presence of SP-A or SP-D 
in comparison to pristine or albumin-conditioned nanoparticles (chapter 7 and 8). 
Furthermore, it could be demonstrated that both stimulating and inhibiting effects on 
nanoparticle clearance by AMs can be related to pulmonary surfactant and the 
underlying complex interplay between surfactant proteins and lipids. In fact, the 
results obtained with native surfactant as a most complex pulmonary surfactant 
model indicate that nanoparticles with different chemical surface modifications might 
be equally taken up by AMs; an observation that could be explained by 
counterbalancing effects between surfactant lipids and proteins (chapter 8).  
 
In summary, these results underline that well characterized nanoparticles might be 
drastically altered once in contact with the alveolar lining fluid, sometimes even to an 
extent that the term nano does not apply anymore, for instance when nanoparticles 
agglomerated once exposed to pulmonary surfactant components. Furthermore, an 
assimilation of clearance for different nanoparticles as observed in chapter 8 points 
out that the interplay of PS components with AMs as an entity represents a 
sophisticated system – and barrier, that efficiently removes particulate matter 
regardless of the material. 
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However, it should be emphasized that the here presented findings are just scatches 
on the surface of a very extensive research field. Although this thesis as a piece might 
contribute to a better understanding of the greater mosaic on what happens after 
nanoparticle landing in the alveoli, still several open questions pop up when looking 
from different perspectives at the respective sides of the pulmonary bio-nano 
interface: 
• With respect to the biomolecule - side, a more detailed insight in the molecular 
mechanisms of surfactant protein binding, in particular calcium-dependency 
and competitivity of the binding, as well as identification of protein domains 
responsible for nanoparticle binding would be valuable information 
contributing to a better understanding of the ongoing processes. 
• A thorough characterization of nanoparticles exposed to native surfactant 
should be conducted, to investigate both binding of surfactant proteins and 
lipids, as the latter obviously seem to play an evenly important role regarding 
cellular effects. Such an approach could eventually lead to a clarification of the 
possibly existing pulmonary corona. 
• On the AM side, uptake mechanisms should be investigated, as well as their 
immunological response to nanoparticles in presence of PS components. In this 
study, a cell line was used as AM model. Therefore, also the interaction with 
AMs from primary sources, as well as with epithelial cell models, should be 
explored. 
Detailed investigations addressing such topics would clear the way for improved 
design of drug delivery systems using nanoparticles for pulmonary applications, but 
could also allow predictions during risk assessments of any kind of inhalable 
nanoparticles. 
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10.  List of Abbreviations 
ACN   Acetonitrile 
ALF   Alveolar lining fluid 
AM   Alveolar macrophage 
ANOVA   Analysis of variance 
AP   Alveolar proteinosiss 
AT 1   Alveolar type 1cell 
AT 2   Alveolar type 2 cell 
BAL   Bronchoalveolar lavage 
BSA   Bovine serum albumin 
CH   Chitosan 
CLSM   Confocal laser scanning microscopy 
CMX   Carboxymethyldextrane 
CRD   Carbohyrate recognition domain 
dae   Aerodynamic diameter 
DC   Dendritic cell 
DLS   Dynamic light scattering 
DPPC   Dipalmitoyl -phosphatidylcholine 
FCS   Foetal calf serum 
HEPES   Hydroxyethyl-piperazineethanesulfonic acid 
Il   Interleukin 
kD   kilo Dalton 
LML   Luminal mucus layer 
mNP   Magnetite nanoparticle 
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MALDI ToF MS Matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry  
MQ   Milli-Q 
NP   Nanoparticle 
NS   Native surfactant 
PA   Palmitic acid 
pBALF   Porcine bronchoalveolar lavage fluid 
PBS   Phosphate buffered saline 
PCL   Periciliary layer 
PL  PL is used here as abbreviation in conjunction with 
phosphatidylcholine-modified magnetic nanoparticles (PL-mNP) 
PMO   Poly maleic olic acid 
POPG   Palmitoyl-oleoyl-phosphoglycerol 
PS   Pulmonary surfactant 
RB   Rose bengal 
RDS   Respiratory distress syndrome 
RPMI   Roswell Park Memorial Institute (cell culture medium) 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM   Scanning electron microscopy 
SP   Surfactant protein 
SPM   Scanning probe microscopy 
ST   Starch 
TNF   Tumor necrosis factor 
TFA   Trifluoroacetic acid 
w/v   Weight by volume 
w/w   Weight by weight 
Ww   Wechselwirkung 
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